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Type 1 diabetes is a life-long chronic disease requiring a life-long treatment 
with insulin. T1D is perceived as an autoimmune disease caused by immune 
cell mediated destruction of pancreatic β cells. T cells of the adaptive immune 
system have been considered to be main mediators of the β-cell destruction. In 
T1D the immunologic tolerance towards β-cell antigens is broken. Immunologic 
tolerance is maintained by central and peripheral tolerance. Peripheral toler-
ance is dictated by the fine balance between effector T cells and regulatory T 
cells (Treg). Advances in the field of T-cell biology have revealed new and more 
dynamic mechanisms in the control of immune reactions. Tregs can lose their 
regulatory features and turn into self-antigen recognizing effector T cells pro-
ducing pro-inflammatory cytokines like IFN-γ and IL-17. The work presented in 
this thesis aimed at assessing the alterations in regulation of T-cell responses 
generated in T1D. The results suggest that generation of regulatory mechanisms 
and effector mechanisms upon T-cell activation are aberrant in children with 
T1D. As a conclusion, the findings of the present thesis provide evidence for the 
enhanced activation of IL-17/IL-22 pathways in association with aberrancies in 
the FOXP3 related regulatory pathways in children with T1D. These findings may 
have therapeutic implications for the prevention and treatment of T1D. 
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Abstract
Jarno Honkanen. Studies of Immune Regulation in Type 1 Diabetes. National Insti-
tute for Health and Welfare. Research 45/2010. 159 pages. Helsinki, Finland 2010. 
ISBN 978–952–245–371–6 (print); ISBN 978–952–245–372–3 (pdf)
Type 1 diabetes (T1D) is considered to be an autoimmune disease. In T1D insulin 
producing pancreatic β cells are destroyed. Th e disease process begins years before 
the clinical diagnosis of T1D. During the pathogenesis of T1D, pancreatic islets are 
infi ltrated by cells of  the immune system and T-lymphocytes are considered to be 
the main mediators of the β-cell destruction. In children with an active β-cell de-
struction process, antibodies against β-cell antigens appear in the blood. Individu-
als at increased risk of developing T1D can oft en be identifi ed by detecting serum 
autoantibodies against β-cell antigens. 
Immunological aberrancies associated with T1D are related to defects in the polar-
ization of T cells and in the function of regulatory mechanisms. T1D has been con-
sidered as an organ-specifi c autoimmune disease mediated by uncontrolled Th 1 –
responses. In human T1D, the evidence for the role of overexpression of cytokines 
promoting cytotoxicity is controversial. For the past 15 years, regulatory T cells 
(Tregs) have been recognized as having a key role in the initiation and maintenance 
of tolerance, limiting harmful autoantigen-specifi c infl ammation processes. It is 
possible that, if regulatory mechanisms fail to be initiated, the subtle infl ammation 
targeting β cells lead to insulitis and eventually to overt T1D in some individuals. 
In the present thesis, we studied the induction of Tregs during the generation of 
T-cell responses in T1D. Impaired up-regulation of Treg-associated genes was ob-
served in activated T-cells cultured in type 1 cytokine environment. We found no 
defect in the induction of genes directing polarization of Th 1 or Th 2 cells. Our da-
ta suggest, that in T1D the induction of regulatory mechanisms is aberrant in cyto-
toxic cytokine environment, which may contribute the pathogenesis of T1D.
T1D has a strong heritable component. However, genetic risk explains only a frac-
tion of the overall risk, and environmental factors must therefore contribute to the 
risk of developing T1D. One of the most studied risk factors is enterovirus infec-
tions. Interestingly, we found children with T1D to have lowered type 1 response 
against coxsackie virus B4 (CVB4). Children with T1D may be more susceptible 
to subtle and/or prolonged CVB4 infections, and they may thus have an increased 
frequency and proportion of CVB-infected β cells. Th is may cause priming of au-
toreactive T cells and β-cell autoimmunity in the pancreatic lymph nodes via anti-
gen presentation by the antigen presenting cells (APCs).
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Recently, a novel T helper cell subset called Th 17 has been discovered. Animal 
models have associated Th 17 cells and especially co-producers of IL-17 and IFN-γ 
with the pathogenesis of T1D. We aimed to characterize the role of Th 17 immu-
nity in human T1D. We found increased secretion of IL-17 and increased mRNA 
expression of IL-17, retinoic acid-related orphan receptor C isoform 2, (RORC2) 
and IL-22 in stimulated peripheral blood mononuclear cells (PBMCs) of T1D pa-
tients. In addition, we observed increased expression of transcription factor Fork-
head box 3 (FOXP3) in stimulated PBMCs of T1D patients. Th is suggests simulta-
neous up-regulation of regulatory mechanisms and the IL-17 pathway in T1D. We 
observed similar expression levels of interferon-γ (IFN-γ) and T-box expressed in 
T cells (T-bet) in stimulated PBMCs of T1D patients and healthy children. How-
ever, IFN-γ expression correlated with IL-17 secretion and co-producers of IL-17 
and IFN-γ were found in children with T1D. In another set of T1D blood samples 
similar up-regulation of Th 17-associated genes and FOXP3 were seen in peripher-
al CD4+ memory T cells. Moreover, IL-17 alone or in synergy with interleukin-1β 
(IL-1β) and IFN- γ was shown to be detrimental for human pancreatic islets in vit-
ro. Our results suggest that IL-17 immunity may be involved in the pathogenesis 
of T1D. Th 17 activation may increase cytokine mediated apoptosis of β cells, and 
thus, the release of β-cell derived auto-antigens, which would accelerate the devel-
opment of β-cell specifi c autoimmunity.
As a conclusion, the fi ndings of the present thesis provide evidence for the en-
hanced activation of IL-17/IL-22 pathways in association with aberrancies in the 
FOXP-related regulatory pathways in children with T1D. Th ese fi ndings may have 
therapeutic implications for the treatment and prevention of T1D.
Keywords: type 1 diabetes, immune regulation, T helper cells, regulatory T cells, 
interleukin-17
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Tyypin 1 diabetesta (T1D) pidetään autoimmuunisairautena. T1D:ssa elimistön 
immuunijärjestelmä tuhoaa haiman insuliinia tuottavat β-solut. Tautiproses-
si alkaa vuosia ennen taudin puhkeamista. T1D:n patogeneesin aikana, haiman 
saarekkeisiin tunkeutuu immuunjärjestelmän soluja, ja -solukuoleman aiheutta-
jana ovat todennäköisesti kehon omia rakenteita tunnistavat T-lymfosyytit. Lapset 
joilla on suurentunut riski sairastua T1D:een voidaan usein tunnistaa havaitsemal-
la seerumista -solujen rakenteita kohtaan tuotettuja autovasta-aineita jo vuosia 
ennen kliinistä diagnoosia.
T1D:een liitetyt immunologiset häiriöt ovat T-solujen vinoutunut erilaistumin-
en ja poikkeava T-soluvasteiden säätelykyky. T1D:een on liitetty liiallinen Th 1 
-solujen toiminta. Näyttö Th 1 -solujen osallisuudesta ihmisen tautipatogeneesiin 
on kuitenkin ristiriitainen. Viimeisen 15 vuoden aikana säätelevien valkosolujen 
toiminta on tunnistettu keskeiseksi mekanismiksi (auto)immuunivasteiden sääte-
lyssä. Jos säätelevien valkosolujen aktivaatio ja toiminta on vajavaista, on mahdol-
lista että immuunijärjestelmä ei kykene taltuttamaan -solujen rakenteita vastaan 
kohdistuvia immuunivasteita. Etenevä -solutuho johtaa lopulta T1D:n puhkeam-
iseen joillekin lapsille.
Tässä väitöskirjassa tutkittiin T-soluvasteiden käynnistymistä, kehittymistä ja 
säätelevien valkosolujen aktivaatiota immuunivasteen käynnistymisen aikana. Ha-
vaitsimme että Th 1-tyyppinen sytokiiniympäristö estää säätelevien valkosolujen 
aktivaatiossa keskeisen transkriptiotekijä FOXP3:n (Forkhead box 3) ilmentymis-
en tyypin 1 diabeetikoilla. Th 1- ja Th 2-tyyppisten eff ektorisolujen erilaistumista 
ohjaavien transkriptiotekijöiden, T-bet ja GATA-3, aktivaatio oli normaali tyypin 1 
diabeetikoilla verrattuna terveisiin lapsiin.
Alttius sairastua tyypin T1D:een on voimakkaasti perinnöllisten tekijöiden 
määräämä. Perinnöllinen alttius selittää kuitenkin vain osan sairastumisen 
kokonaisriskistä, ja siten ympäristötekijöillä on merkitystä T1D:n synnyssä. Eräs 
eniten tutkituista ympäristötekijöistä ovat enterovirusinfektiot. Havaitsimme että 
tyypin 1 diabeetikoilla on heikentynyt kyky coxsackievirus B4:n (CVB4) vastus-
tuskyky. Tyypin 1 diabetespotilaiden virushäätö näyttäisi olevan heikentynyt, jol-
loin toistuvat ja pitkittyneet -solujen virusinfektiot voivat johtaa lisääntyneeseen 
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-solukuolemaan. -solurakenteiden vapautuminen kuolevista soluista voi 
puolestaan johtaa kiihtyneeseen antigeeniesittelyyn haiman imusolmukkeissa, ja 
aikaansaada -soluja tunnistavien T–solujen syntymisen.
Hiljattain on löydetty uusi T-auttajasolujen alaluokka, Th 17-solut. Erityisesti in-
terlukiini-17:a ja interferoni-γ:aa tuottavat Th 17-solut ovat osoittautuneet pato-
geenisiksi T1D:n eläinmalleissa. Tavoitteemme oli kuvata Th 17-solujen osuutta 
ihmisen T1D:ssä. Havaitsimme että tyypin 1 diabeetikoiden stimuloidut valko-
solut ilmensivät runsaammin IL-17 sytokiiniä, sekä lähetti-RNA– että proteiini-
tasolla. Lisäksi havaitsimme Th 17-solujen toimintaan liittetyn interleukiini-22 ja 
transkriptiotekijöiden ROR-C2 (retinoic acid-related orphan receptor C isoform 
2) ja FOXP3 voimakkaamman lähetti-RNA ilmentymisen tyypin 1 diabeetikoi-
den stimuloiduissa valkosoluissa. Samanaikainen voimakkaampi FOXP3 ilmenty-
minen stimuloiduissa valkosoluissa Th 17-solujen merkkiaineiden kanssa on yllät-
tävä havainto, mikä saattaa viitata häiriintyneeseen Th 17-soluvasteiden säätelyyn 
tyypin 1 diabeetikoilla. Th 1-tyyppisten solujen kehittymistä ohjaavan T-bet:in ja 
liukoisen merkkiaineen IFN-γ ilmentyminen oli samalla tasolla sekä terveillä et-
tä tyypin 1 diabetekseen sairastuneilla lapsilla. IFN-γ tasot kuitenkin korreloivat 
IL-17 erityksen kanssa diabeteskseen sairastuneilla lapsilla. Lisäksi havaitsimme 
joidenkin T1D:een sairastuneiden lasten stimuloitujen valkosolujen ilmentävän 
samassa solussa IL-17 ja IFN-γ merkkiaineita. Tutkimme Th 17 immuniteettiin li-
itettyjen geenien ilmentymistä myös perifeerisen veren muistivalkosoluissa. Ha-
vaitsimme että IL-17, IL-22 ja FOXP3 lähetti-RNA ilmentyminen oli koholla jo ki-
ertävissä perifeerisen veren T –auttajamuistisoluissa T1D:ssa. Osoitimme lisäksi 
että IL-17 yksin tai yhdessä muiden tulehdusreaktiota voimistavien merkkiainei-
den, kuten IL-1β ja IFN-γ, kanssa lisää saarekesolujen kuolemaa in vitro. Th 17 ak-
tivaatio voisi siten kiihdyttää -solukuolemaa, ja edesauttaa -soluihin kohdistu-
van autoimmuniteetin syntymistä. 
Johtopäätöksenä tämän väitöskirjan tuloksista on että voimistunut IL-17/IL-22 
välitteinen immuniteetti ja häiriintynyt FOXP3 välitteisten säätelymekanismien 
aktivaatio saattaa olla osallisena T1D:een johtavassa patogeneesissä. Löydöksillä 
saattaa olla hoidollista merkitystä T1D:ssa.
Avainsanat: tyypin 1 diabetes, immuunivasteen säätely, T-auttajasolut, regulatori-
set T-solut, interleukiini-17
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IPEX  immune dysregulation polyendocrinopathy enteropathy X-linked
iTreg  inducible regulatory T-cell
MDA5  melanoma diff erentiation-associated gene 5
MHC I, MHC II major histocomatibility complex
MIN-6  mouse insulinoma cell line 6
MODY  maturity-onset diabetes of the young
NFATc2  nuclear factor of activated T cells, calcineurin-dependent
NK  natural killer cell
NOD  non-obese diabetic
NOS2A  nitric oxide synthase 2A
nTreg  natural regulatory T -cell
OGTT  oral glucose tolerance test
PBMC  peripheral blood mononuclear cells
PBS  phosphate buff ered saline
PFA  paraformaldehyde
PHA  phytohemagglutinin
RNA  ribonucleic aid
RORC2  retinoic acid-related orphan receptor C isoform 2
RT-qPCR  reverse transcription quantitative polymerase chain reaction
STAT  signal transducer and activator of transcription
T1D  type 1 diabetes
T2D  type 2 diabetes
T-bet  T-box expressed in T cells
TCR  T-cell receptor
TGF-β  transforming growth factor β
Th 1  T helper 1
Th 17  T helper 17
Th 2  T helper 2
Th 3  T helper 3
Th p  T helper precursor
TLR-4  toll-like receptor 4
TNF-α  tumor necrosis factor alpha
Tr1  regulatory T-cell, Tr1 type 
Treg  regulatory T-cell  
VNTR  variable nucleotide tandem repeat
ZnT8  zinc transporter 8
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1 Introduction
Type 1 diabetes (T1D) is a life-long chronic disease. In type 1 diabetes insulin-pro-
ducing β cells in the islets of Langerhans are destroyed, resulting in total lack or in-
suffi  cient production of insulin. Th is leads to hyperglycemia, glycosuria and ke-
tonuria and eventually, if not treated with exogenous insulin, to death.
Symptoms resembling those of T1D were characterized for the fi rst time in 
1552 BC in Egyptian writings. However, it was not until 1674 that T. Willis discov-
ered sugar in the urine of patients with diabetes mellitus. Over a hundred years lat-
er, in 1776, M. Dobson also found sugar in the blood of diabetic patients.
In 1889, Minkowski and von Mering discovered that dogs subjected to the 
surgical removal of the pancreas developed diabetes. Pancreas extract was used as 
a treatment for diabetes in the year 1908, and the treatment reduced the blood glu-
cose level of diabetes patients. Insulin was isolated for the fi rst time from a dog’s 
pancreas in 1921, and a year later insulin was successfully used to treat a diabetic 
patient for the fi rst time. 
T1D is perceived as an autoimmune disease caused by immune cell mediated 
destruction of pancreatic β cells. In 1965, Willy Gepts published an article show-
ing the infi ltration of immune cells in the pancreatic tissue [1]. Th e autoimmune 
nature of T1D was ultimately confi rmed when the genetic association of T1D with 
the HLA gene region [2] and the presence of islet cell-specifi c autoantibodies [3] 
was demonstrated in patients with T1D. T cells of the adaptive immune system 
have been considered to be the main mediators of the β-cell destruction [4], and 
defects in T-cell polarization and immune regulation have been associated with 
T1D. Th e pathogenesis of T1D has been considered to result from a breakdown of 
immunologic tolerance towards β-cell antigens. Immunologic tolerance is main-
tained by two major phenomenon; central and peripheral tolerance. Peripheral tol-
erance is dictated by the fi ne balance between eff ector T cells and so called regula-
tory T cells (Treg). Recent advances in T cell research have provided new insights 
into the dynamics and regulation of T cell responses. Not only the balance between 
fully committed eff ector T cells and regulatory T cells, but also the plasticity be-
tween these phenotypes seems to play a role in autoimmunity and tolerance [5-
7]. Novel T-cell subsets, like Th 17 cells, have been characterized, and the function 
of Tregs has been demonstrated to be more dynamic and plastic than previously 
thought. Better understanding of the mechanisms generating and regulating T-cell 
responses is required for the development of eff ective therapies for T1D. Th e work 
presented in this thesis aimed at assessing the alterations related in generation and 
regulation of T-cell responses in T1D.
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2  Review of the literature
2.1 Classifi cation of diabetes in children
Diabetes mellitus is a heterogeneous group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both. 
Th e current classifi cation of diabetes mellitus includes four main categories; type 
1 diabetes, type 2 diabetes, diabetes with known monogenic defect and gestational 
diabetes. Type 1 diabetes can be further divided into two subclasses; type 1A, and a 
rare type 1B diabetes [8]. T1D is caused by a defi ciency in insulin secretion due to 
the loss of pancreatic β cells, and the disease requires life-long treatment with ex-
ogenous insulin. Without the body’s own insulin production the body loses its abil-
ity to utilize carbohydrates as an energy source.  
T1DA diabetes is considered as an autoimmune disease, which is developed 
due to the T-cell-mediated destruction of β cells in the islets of Langerhans of the 
pancreas. In children with an active β-cell destruction process, autoantibodies 
against β-cell structures appear in the circulation. In T1DB the cause for β-cell de-
struction is not known. Th is type of diabetes is a very rare condition in Caucasian 
populations. However, in Japan it comprises of 10% of all T1D cases. T1DB diff ers 
from the T1DA in that it has no HLA –association and the mechanisms of β-cell 
destruction do not include β-cell autoimmunity. 
Type 1A diabetes (T1D hereaft er) is the most common form of  diabetes in 
children worldwide, and approximately 80% of the children with diabetes has T1D 
[9]. In addition, there are several rare forms of diabetes diagnosed in the early 
childhood or in late youth/early adulthood. Th ese types of diabetes are typically 
monogenic, and caused by an inherited mutation in certain genes involved in the 
insulin secretion of β cells (Th e Expert Committee on the Diagnosis and Classifi ca-
tion of Diabetes Mellitus 2003; American Diabetes Association 2006). Th ese forms 
of diabetes are characterized by the onset of hyperglycaemia during childhood or 
early adulthood (<25 years of age), and are referred to as maturity-onset diabe-
tes of the young (MODY). MODY is characterized by impaired insulin secretion 
with minimal or no defects in insulin action [10-12]. Patients with MODY are di-
vided into diff erent categories according to the specifi c mutations in the genes reg-
ulating the functions of β cells [13].  In another form of diabetes caused by point 
mutations in the mitochondrial DNA, deafness has been associated with diabetes 
mellitus [14, 15]. An A to G transversion mutation in the tRNALeu(UUR) gene is 
found in about 1.5% of the diabetic patients worldwide [16]. In some cases, diabe-
tes is caused by genetic defects in insulin action. Functional insulin is cleaved from 
the  precursor molecule proinsulin. Some types of diabetes are caused by mutations 
interfering the enzymatic cleavage of proinsulin molecules into functional insu-
lin molecules. Such diabetes types are inherited in an autosomal dominant pattern 
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[17, 18]. In the much more prevalent type 2 diabetes (T2D), the disease is caused 
by a combination of tissue resistance to insulin and defi ciency in insulin secretion 
from the pancreas. Individuals with T2D have relative rather than absolute insulin 
defi ciency [19, 20].  Such individuals with this type of diabetes may survive, at least 
initially, without insulin replacement therapy (Th e Expert Committee on the Di-
agnosis and Classifi cation of Diabetes Mellitus 2003; American Diabetes Associa-
tion 2006). Th e etiology of T2D is largely unknown, but obesity and reduced phys-
ical activity have been associated with the appearance of T2D. In the past, T2D was 
considered a disease of adults and older individuals. Recently, however, the inci-
dence of T2D has been increasing even among children and adolescents [19, 20]. 
2.2 Epidemiology of T1D
Finland has the highest incidence of T1D in the world [21, 22], and the prevalence 
is continuously rising [23]. Th e overall incidence of T1D in Finnish children dou-
bled between 1980 and 2005,  and the increase was particularly steep in children 
aged 0-4 years. Th e incidence of T1D was 64.2 per 100 000 children under the age 
of 15 in the year 2005 [24].  Th e incidence rate of T1D was predicted to reach 50 
per 100 000 children in 2010, if the increase had remained linear from 1950s [25]. 
Th e incidence of T1D is highest in Western societies, and there are clear geo-
graphical and ethnic diff erences. Particularly high incidences (>20 per 100 000 per 
year in 1994) have been reported in Finland, Sweden, Norway, Portugal, Canada 
and New Zealand [26]. Moderately high incidences are found in the United States 
and in European countries. For example, the incidence rate in France was 9.3 per 
100 000 in 1995, and in the United States 14.8 per 100 000 in 1994. Lower incidenc-
es have been recorded in Eastern Europe countries than in other parts of Europe. 
For example, the incidence is 3.5 times higher in Nordic countries than in Estonia 
[26, 27]. Even more striking diff erence can be seen between Finland and Russian 
Karelia; the incidence of clinical type 1 diabetes is six times higher in Finland [28]. 
Th e lowest incidence globally (<1/100,000 per year) has been detected in popula-
tions from China and South America [26]. A low incidence (1-10 per 100 000) has 
been found in some parts of Asia, such as in Japan, where it is about 1.5 per 100 000 
[29], as well as in South America [30] and in Africa [31, 32].
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2.3 Clinical features of autoimmune T1D
2.3.1 Diagnostic criteria
Th e clinical signs of diabetes are associated with hyperglycaemia and osmotic diu-
resis. Untreated insulin defi ciency leads to the use of fats as an energy source and 
to elevated levels of ketoacids in the body. Th is results in nausea and hyperventi-
lation as clinical symptoms. Unexplained weight loss also oft en accompanies the 
above-mentioned symptoms.  If blood glucose level exceeds 11.1mM or the fast-
ing glucose concentration is above 7.0 mM, diabetes is clinically diagnosed. Dia-
betes may also be diagnosed by performing an oral glucose tolerance test (OGTT), 
in which the plasma glucose level is measured 2 hours aft er orally ingesting 75 g 
of glucose. If the plasma glucose level exceeds 11.1 mM the subject is considered 
diabetic. (Th e Expert Committee on the Diagnosis and Classifi cation of Diabetes 
Mellitus 2003; American Diabetes Association 2006). T1D and T2D can be distin-
guished from each other by detecting autoantibodies against the islet cell struc-
tures, typically found in 90% of patients with T1D at the time of diagnosis. About 
50% of patients with T1D are diagnosed under the age of 14 years. Most patients 
with T1D have no detectable fasting C -peptide secretion remaining. Th e diagnosis 
of other specifi c diabetes syndromes than T1D requires the gathering of more de-
tailed clinical information such as the ethnic background of the patient, age of on-
set, personal history of organ-specifi c autoimmunity, obesity and acute versus sub-
tle onset of the disease.  
2.3.2 Autoimmunity in T1D
Th e fi rst evidence for the immune mediated pathogenesis of T1D was presented 
in the mid-1960s when Willy Gepts published a study characterizing the infi ltra-
tion of immune cells in the infl amed islets of dead patients with acute onset diabe-
tes [1]. Th e pathogenesis of T1D is characterized by the infi ltration of mononuclear 
cells such as CD4+ helper cells and cytotoxic CD8+ cells, macrophages, natural kill-
er cells and B cells into the pancreatic islets [33, 34]. Th e autoimmune nature of the 
pathogenesis of T1D became more evident when the association of T1D with other 
autoimmune diseases such as autoimmune thyroiditis and autoimmune adrenalitis 
was recognized [35-37]. Th e autoimmune nature of T1D was ultimately confi rmed 
when the genetic association of T1D with HLA gene region [2] and the presence 
of islet cell-specifi c autoantibodies was demonstrated in patients with T1D [3, 38]. 
Th e aberrant hyperexpression of both MHC I and MHC II molecules in the pan-
creas further suggested the participation of immunological mechanisms in the 
pathogenesis of T1D [34, 39, 40]. Increased expression of MHC Class I molecules 
A, B and C has been observed in the pancreatic islets cells of acute onset immune-
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mediated diabetes [39, 40]. Infi ltrating immune cells are activated and express in-
creased levels of MHC Class II and interleukin (IL)-2 receptor molecules on their 
surface. Endocrine cells in the normal pancreas do not express Class II MHC mol-
ecules [41-43]. Animal models of T1D strongly suggest that T lymphocytes are the 
main mediator of β-cell destruction [4]. It seems most likely that in T1D, tolerance 
to β-cell antigens is broken and insulin producing β cells in the pancreas are de-
stroyed by the host’s own immune system.  
In children with an active β-cell destruction process, antibodies against β-cell 
structures appear in the peripheral blood. Furthermore, individuals at increased 
risk of developing T1D can oft en be identifi ed by detecting antibodies against β-cell 
structures in the peripheral blood. Autoantibodies refl ecting the β-cell  destruction 
include islet cell antibodies (ICAs), insulin autoantibodies (IAA), glutamic acid 
decarboxylase (GAD65) autoantibodies, and autoantibodies to the tyrosine phos-
phatases IA-2 and IA-2beta [44-52]. Recently, antibodies to the cation effl  ux trans-
porter ZnT8 have been detected in 60-80% of new onset T1D patients [53]. Of the 
T1D related autoantibodies, insulin is the only protein with limited expression in 
β-cells and thymic medullar epithelial cells. Several clinical studies have shown the 
appearance of autoantibodies in the course of T1D pathogenesis. However, there is 
no evidence that autoantibodies related to T1D play a direct role in the pathogen-
esis of the disease. 
Animal models also support the T-cell rather than B-cell-mediated initiation 
of β-cell destruction. Two animal models, the NOD mouse and BB rat, have been 
especially valuable in studying the pathogenetic mechanisms of autoimmune dia-
betes. Th e NOD mouse is an inbred mouse strain that spontaneously develops au-
toimmune mediated diabetes [54]. Wicker et al. showed in the 1986 that transfer-
ring splenocytes from diabetic NOD mice to healthy irradiated mice  >6wks of age 
initiates the diabetes in the healthy mice [55]. Later, it was shown that the trans-
fer of T cells from diabetic NOD mice to healthy NOD mice transfers the disease, 
without autoantibodies being present [4, 56]. Autoimmune-mediated diabetes can 
be prevented in NOD mice by the administration of antibodies against T cells, sup-
porting the role of T cells in the pathogenesis of T1D [57]. Prediabetic NOD mice 
were also protected from overt diabetes when antibodies targeted the molecules in-
volved in the antigen recognition [58, 59], cellular activation [60] or pancreas hom-
ing receptors [61] were administered to the mice. Rabinovitch et al. succeeded in 
preventing disease in NOD mice by administering antibodies targeting cytokines 
mainly responsible for orchestrating T -cell responses, particularly Th 1-directing 
cytokines such as IFN-γ, IL-12 and TNF-α  [62]. In BB rats neonatal thymectomy 
reduced the frequency of spontaneous diabetes mellitus from 27% to 3% empha-
sizing the role of T-cell-mediated autoimmune processes in the pathogenesis of au-
toimmune diabetes [63].
Th e role of T cells in the pathogenesis of T1D is also supported by the ob-
servation that drugs down regulating T-cell activity prolong the survival of islet 
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transplants in patients with T1D. Immune suppressors such as cyclosporine A and 
rapamycin have been used in animal models and in clinical trials for immune sup-
pression to protect transplanted islets. However, in humans, the side eff ects of these 
drugs have been severe, and these treatments are consequently not in clinical use. 
In the treatment of T1D, modifi ed antibody targeting the CD3 (hOKT3γ1) mole-
cule on the surface of T lymphocytes is already undergoing clinical trials. Th e an-
ti-CD3 infusion induces tolerance, and prolongs insulin production aft er diagno-
sis [64].
In humans, allogeneic bone marrow transplantation transferred T1D from af-
fected sibling to the non-diabetic patient [65]. T-cell involvement in the course of 
pathogenesis of T1D is evident. However, the detailed roles of CD4+ and CD8+ cells 
during the pathogenesis of T1D remain unresolved. Some studies have demon-
strated that CD4+ T helper cells are responsible for the initiation of the pathogenic 
process in pancreatic tissue, but the ultimate destruction of β cells is carried out by 
cytotoxic CD8+ lymphocytes (CTLs) [66, 67]. Animal models have shown that the 
transfer of CD4+ T helper cells initiates autoimmune diabetes, but the  transfer of 
CD8+ T cells alone does not. It has also been demonstrated in NOD mice that the 
parallel transfer of both CD4+ and CD8+ T -cells greatly increases the rate and the 
proportion of healthy recipient mice developing autoimmune diabetes [68]. Dur-
ing insulitis, T cells are the predominant cell type infi ltrating the islets of Lang-
erhans. IFN-γ-secreting Th 1 cells prepared from diabetic NOD mice have been 
shown to initiate pathogenic events in the pancreatic islets, whereas the transfer of 
Th 2 type cells secreting mainly IL-4 resulted in non-destructive peri-insulitis with 
no β-cell death [69]. Th e infi ltration of type 1 cytokines secreting lymphocytes is 
associated with the destruction of β cells in the infl amed islets of NOD mice. In di-
abetes-prone NOD mice, elevated levels of IL-12, IL-18, and IFN-γ were observed, 
supporting the role of Th 1-type cells in the pathogenesis of  diabetes [70]. In the 
same study it was recognized that diabetes-resistant NOD mice did not show up-
regulation of Th 1-related cytokines, suggesting the Th 1-cytokine milieu to be in-
volved in the pathogenetic processes of autoimmune diabetes. Moreover, sustained 
IL-4 expression in the pancreas of diabetes-resistant NOD mice suggested that the 
local cytokine milieu plays a critical role in the regulation of local immune re-
sponses.
According to Foulis et al. [71], over 40% of the mononuclear cells infi ltrated in 
the pancreatic islets  of patients with T1D expressed IFN-γ, a hallmark cytokine for 
Th 1-type cells. Increased expression of IFN-α mRNA was observed from the pan-
creas biopsy of a newly diagnosed T1D patient, supporting the idea that cytotoxic 
T-cell responses participate in the pathogenesis of T1D [72, 73]. Higher IFN-γ se-
cretion of phytohemagglutinin (PHA)-stimulated PBMCs of T1D patients has also 
been observed when compared to healthy children [73]. However, there are studies 
suggesting impaired Th 1 responsiveness in PBMCs from children with T1D, and 
the results from human studies are thus contradictory.
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2.4 Immune system
2.4.1 Immunological tolerance
Immunological self-tolerance is critical for the prevention of autoimmunity and 
maintenance of immunological homeostasis. Immunological homeostasis is main-
ly maintained by two mechanisms; central and peripheral tolerance. Central toler-
ance refers to the deletion of T cells with an excessively high T-cell receptor (TCR) 
affi  nity towards the body’s own peptides presented in MHC class I and class II mol-
ecules in the thymus [74-76]. It has been suggested that central tolerance is aber-
rant in patients suff ering from autoimmune disease and that autoreactive T cells 
escape from the thymus and prime the immunological systems towards autoim-
munity. However, autoreactive T cells are also released from the thymus in healthy 
people, but in healthy people these potentially pathogenic autoreactive T cells are 
controlled in the periphery. Th is phenomenon is known as peripheral tolerance. 
T cells arise from the hematopoietic precursor cells that are born or generat-
ed in the bone marrow. Th ese precursor cells then migrate to the thymus and begin 
the maturation process before they can enter into the peripheral blood stream. In 
order to produce T cells that have appropriate responses to discriminate between 
self and non-self structures in the periphery, the development of T cells takes place 
in a specialized organ, the thymus [77]. In the thymus T cells recognize their spe-
cifi c antigens bound to self-MHC molecules via their TCR. Th e early maturation 
process of T cells consists of several sequential checkpoint events [78]. In the later 
stages of development, thymocytes are double positive regarding CD4+ and CD8+ 
surface antigens. Th ese developing CD4+CD8+ thymocytes are the subject of pos-
itive and negative selection. During positive selection the affi  nity of TCR is tested 
on the Ag-MHC complex, and only those thymocytes that possess a high enough 
affi  nity are allowed to live. Th ymocytes with too low an affi  nity are directed to the 
apoptotic pathway, and thymocytes that pass the positive selection do not to have 
an excessively high affi  nity towards the body’s own peptides. At this stage, develop-
ing thymocytes are diff erentiated to express only either CD4+ or CD8+ antigens on 
their surface. Aft er the selection, fully matured, naïve T cells migrate to secondary 
lymphoid organs where they meet their specifi c antigen and are activated. 
For the past 15 years, thymus derived natural regulatory T cells (nTregs), ex-
pressing the signature transcription factor Forkhead box 3 (FOXP3), have been 
recognized as key moderators in maintaining immunological homeostasis, ex-
tinguishing infl ammation processes initiated by the autoreactive T cells. Th e role 
of Tregs in shutting off  unwanted, harmful immune reactions has been described 
in many diseases [reviewed in [79-83]]. By far the most signifi cant evidence for 
the role of Tregs in immunological homeostasis is the fact that both humans and 
mice defi cient in Tregs suff er from widespread autoimmune diseases [84]. Tregs 
are known to develop from thymocytes with a moderately high TCR affi  nity to the 
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body’s own peptides. It is not known why some high affi  nity thymocytes escape and 
diff erentiate into Treg cells. Neither is the antigen specifi city of the cells entering 
the Treg development pathway known [85]. It is assumed that Treg cells are pol-
yclonal populations and that they are able to recognize a wide repertoire of  both 
self-derived and exogenous antigens [85]. Th e autoimmune regulator gene (Aire) 
promotes the expression of tissue-specifi c antigens in the medullary epithelial cells 
in the thymus [86]. Th e deletion of self-reactive thymocytes is critically regulated 
by the expression of the Aire gene [74, 87].
2.4.2 T lymphocytes
Th e human adaptive immune system consists of T and B lymphocytes. T cells can 
be divided into two main categories, CD4+ T helper cells and CD8+ cytotoxic T 
cells. Th e cells of the acquired immune system have the capability to form a mem-
ory of a pathogen that they have encountered. Th us, the immune system can dra-
matically improve its potential to resist pathogens. T lymphocytes recognize their 
specifi c target antigen bound to HLA molecules. Cytotoxic CD8+ T cells recognize 
peptides bound to HLA I class molecules, while CD4+ T helper cells recognize pep-
tides bound to HLA II molecules. MHC I molecules are expressed in all cells of the 
body, whereas MHC II molecules are only expressed by professional antigen-pre-
senting cells such as dendritic cells (DCs), monocytes, macrophages and B-cells.  
CD4+ T helper cells provide help for other cell types by secreting soluble cy-
tokines. Th ese cytokines direct the responses of the recipient cells, either stimulat-
ing or inhibiting them.
Cytotoxic CD8+ T cells kill the body’s own cells infected with intracellular 
pathogens such as viruses. CD8+ cells recognize their specifi c antigenic peptides 
presented on HLA class I molecules. When the engagement of the TCR-Ag-MHC 
I complex occurs, CD8+ cells initiate their death-mediating processes. CD8+ cyto-
toxic T cells kill their target cells by perforin and/or granzyme killing. Th ey can al-
so induce apoptosis in their target cells by FAS-FASL interaction or by secreting 
soluble cytokines such as TNF-α and IFN-γ.
2.4.3 T helper cells
Th e fi rst observation that CD4+ T cells are divided into at least two distinct sub-
types originally came from mouse studies [88]. Soon aft er, the functional dichoto-
my of T helper cells was confi rmed to also be present in humans [89]. CD4+ T cells 
were originally divided in two functionally diff erent categories, Th 1 and Th 2  cells, 
both of which have a diff erent potential to augment B-cell responses in vitro [90]. 
Nowadays, further CD4+ T-cell subsets have been defi ned. In addition to Th 1 and 
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Th 2, novel eff ector CD4+ T cell subsets called Th 17 cells and a CD4+ T-cell class 
mediating immune regulation functions, known as Tregs, have been characterized. 
T helper cell precursors originate from the bone marrow and mature in the thy-
mus. From the thymus, mature T cells migrate into the peripheral blood circula-
tion. Activation of Th  cells takes place in the lymph nodes aft er the interaction of 
their antigen-specifi c T-cell receptor with the antigen-MHC class II complex pre-
sented by the APCs. Figure 1 illustrates the diff erentiation of CD4+ T-cell subsets, 
and factors contributing to the activation and diff erentiation process of these sub-
sets in humans. Th e diff erentiation of Th  cells into either Th 1, Th 2  or Th 17 eff ec-
tor or the Treg phenotype is mainly controlled by the cytokine stimuli of their en-
vironment and the strength of the MHC II-Ag-TCR interaction. APCs are the most 
important regulators of the cytokine environment in the tissue. Several factors in-
fl uence the diff erentiation process, including the type of APCs, the strength and 
quality of antigen exposure, ligation of co-stimulatory molecules and the local cy-
tokine environment. Dendritic cells (DC) have been suggested to be the primary, if 
not exclusive, type of APCs presenting peptides to naïve CD4+ T cells in an MHC 
II restricted fashion [91].
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FIGURE 1. Differentiation of human CD4+ T helper cell subsets. T helper cell precursors (Thp) 
are generated in the bone marrow. From there they migrate to to the thymus and under-
go through the positive and negative selection. Naïve T cells then migrate to the peripher-
al blood circulation. Th cells are activated in the lymph nodes when APCs present peptides 
bound onto their HLA class II molecules. After the activation of Th cells, cytokines secreted 
mainly by the APCs direct the differentiation process either towards effector Th1, Th2, or 
Th17 phenotypes or towards the iTreg phenotype. nTregs are already committed to the reg-
ulatory phenotype in the thymus. Tregs have been characterized to show signifi cant plastic-
ity under certain experimental conditions, and are able to convert into either Th1 or Th17 
phenotypes [7, 92] (dotted lines in the fi gure). Th17 cells may also begin to express IFN-, a 
hallmark cytokine of Th1 cells (dashed line in the fi gure). Th17 cells expressing IFN- are po-
tentially highly pathogenic, and in islet cell antigen-specifi c T cell transfer experiments, these 
cells have been shown to initiate -cell autoimmunity in naïve mice recipients [5]. 
Th e activation and diff erentiation of CD4+ T helper cells requires at least two sig-
nals. Th e fi rst is delivered through the engagement of TCR, and the second signal 
is delivered through the co-stimulatory molecules such as CD28 and ICOS (Fig-
ure 2).
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FIGURE 2.  Activation scheme of CD4+ T cells. TCR engagement is the fi rst requirement for the 
activation of CD4+ T-cells. APCs present peptides bound onto MHC II class molecules. For full 
activation, the second signal needed, which is delivered through the interaction of co-stimu-
latory molecules on the surface of APCs and their ligands on the surface of CD4+ T cells. The 
binding of adhesion molecules such as ICAM-1 provides stability for the cell-cell interaction 
and enables the endothelial transmigration of activated CD4+ T cells to the site of infl amma-
tion. Cytokines secreted by the APCs direct the development of activated CD4+ T cells to ful-
ly functional effector T cells or Tregs.
2.4.4 Th 1 and Th 2 cells
Th e most critical cytokines regulating the Th 1/Th 2 polarization of the Th  cells are 
IL-12 and IL-4, directing Th 1 and Th 2 polarization, respectively. Uncontrolled or 
unbalanced Th  helper cell responses have been associated with allergy and autoim-
mune disease pathogenesis. Th 1 cells have been linked to many chronic autoim-
mune diseases whereas Th 2 –cells are oft en linked to atopic and allergic condi-
tions [93]. 
Th 1 cells predominantly release IFN-gamma and IL-2, TNF-α, and lympho-
toxin, and direct the immune response towards cell-mediated immunity, delayed-
type hypersensitivity (DTH) and macrophage activation. Th us, Th 1 cells promote 
the clearance of intracellular pathogens, e.g. Leishmania major and Listeria mono-
cytogenes. Th 1 responses have been associated with many autoimmune diseases. 
Th 1 cells characteristically express the IFN-γ receptor-β chain, IL-12 receptor β 
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chain [94], IL-18 receptor [95], CXCR3 and CCR5 chemokine receptors [96] on 
their surface, whereas Th 2 cells preferentially express CCR3 and CCR4 cell surface 
receptors [97, 98]. Th e STAT4 cascade is activated when IL-12 binds to the IL-12 
receptor on the cell surface. An activated STAT4 homodimer molecule is active-
ly transported to the nucleus, where it recognizes specifi c DNA sequences and ac-
tivates transcriptional events of its target genes, IFN-γ, IL-12Rβ2 and T-box ex-
pressed in T cells (T-bet). IFN-γ binding to its receptor leads to activation of the 
STAT1 signaling cascade. Th e STAT1 homodimer eventually binds to the promot-
er region of T-bet and induces the transcriptional activity of T-bet, thus enhanc-
ing the Th 1 diff erentiation events in the cell [99, 100]. Increased susceptibility to 
microbial pathogens and viruses has been observed in mice defi cient in  IFN-γ, 
IFN-γR1, IFN-γR2 or the signaling molecule STAT1 [101-106]. Humans with mu-
tations in IFN-γ signaling pathway components have been characterized to have 
profound immunodefi ciencies, resulting in severe intracellular bacterial infections 
[107-110]. T-bet is a master regulator of the induction and maintenance of the Th 1 
phenotype of CD4+ T cells [111]. T-bet belongs to a conserved family of transcrip-
tion factors known as the T-box family. Th is family of transcription factors is con-
served throughout diverse species, and they play a key role in directing early de-
velopmental processes. TCR engagement has a central role in the control of T-bet 
expression. Aft er TCR-Ag-MHC II interaction, the IFN-γR/STAT1 signaling cas-
cade is recruited and the expression of T-bet is rapidly up-regulated [112, 113]. 
IFN-γ secretion by NK cells, macrophages and DCs induce the expression of T-
bet, which in turn causes chromatin remodeling of the IFN-γ locus [114]. One of 
the key mechanisms by which T-bet induces and drives Th 1 diff erentiation is up-
regulation of the IL-12Rβ2 subunit of the IL-12 receptor. Up-regulation of the IL-
12 receptor leads to increased STAT4 signaling and thus optimizes the IFN-γ pro-
duction, further strengthening the development of the Th 1 phenotype [112, 114]. 
In activated and diff erentiating T cells, T-bet effi  ciently inhibits the transcription of 
genes related to the induction and functions of Th 2 cells (Figure 3). 
Th 2 cells typically secrete cytokines activating B cells, such as IL-4, IL-5, and 
IL-13, to produce antibodies providing protection against extracellular pathogens 
[115, 116] including helminths and nematodes. IL-4 is the cytokine responsible for 
directing the maturation of the Th p cells towards the Th 2 direction. Th e develop-
ment of the Th 2 phenotype is controlled by the activation of the STAT6 signaling 
cascade. Binding of IL-4 to its receptor recruits STAT6 molecules to bind to the cy-
toplasmic tail of the IL-4 receptor. STAT6 molecules are then phosphorylated by 
Jak kinases and are homodimerized and translocated to the nucleus [117]. In the 
STAT6 signaling pathway,  the transcription factor mainly responsible for the in-
duction of Th 2-type genes is GATA-3, and the recognition sequence G/A/T/A can 
be found at least in the promoter region of IL-5, IL-13 and IL-4R genes (Figure 4). 
GATA-3 also has a role in chromatin remodeling of the Th 2 loci in chromosome 
fi ve. Th 1 and Th 2 cell development rapidly diverges aft er the antigenic recognition. 
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Th e signaling pathways directing the diff erentiation process of distinct subsets are 
robust and counter-regulatory. Th 1-type cytokines have counter-regulatory eff ects 
on Th 2 cells, and vice versa [115, 118].
FIGURE 3. Signaling directing the differentiation of activated naïve T helper cells towards the 
Th1 phenotype. After TCR-Ag-MHC II interaction, the IFN-R/STAT1 signaling cascade is re-
cruited and induces the expression of transcription factor T-bet. IL-12 ligation leads to STAT4 
dimerization and phosphorylation and induces the expression of the IL-12R2 subunit and 
IFN-. IFN- strengthens its own expression through a positive feedback loop, which leads to 
rapid Th1 phenotype stabilization. Th1 type signaling effi ciently inhibits the induction of the 
Th2 phenotype.
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FIGURE 4. IL-4 is the most critical cytokine directing the differentiation of activated naïve T cells 
towards the Th2 phenotype. IL-4 ligation induces STAT6 signaling and GATA-3 transcription. 
Transcription factor GATA-3 promotes the transcription of Th2 type cytokines and their re-
ceptor counterparts. TCR signaling gives rise to the expression of c-maf, promoting the ex-
pression of Th2 type genes. GATA-3 is an effi cient inhibitor of Th1 phenotype development 
in the activated naïve T cells.
2.4.5 nTreg, Tr1, and Th 3 cells
Th e importance of CD4+CD25+FOXP3+ Tregs has been recognized since 1995. 
During that year, Sakaguchi et al. demonstrated that a small proportion of acti-
vated CD4+CD25+ cells contributed to the maintenance of self-tolerance by down-
regulating the immune response to self and non-self antigens in an Ag-nonspe-
cifi c manner. Tregs were able to suppress the proliferation of CD8+ T cells and 
established Th 1 and Th 2 cells by secreting soluble cytokines but also by direct cell-
cell contact. Inoculation of thymus-and spleen-derived CD25+ depleted CD4+ cells 
from Balb/nu/+ mice into BALB/c athymic nude (nu/nu) mice caused a variety of 
autoimmune diseases such as thyroiditis, gastritis, insulitis, sialoadenitis, adrenali-
tis, oophoritis, glomerulonephritis and polyarthritis in all recipients [80]. Relative-
ly soon aft er the rediscovery of ‘suppressor’ T cells by Sakaguchi et al., it was dem-
onstrated that  CD4+ cells expressing high levels of CD25+ on their surface had the 
potential to inhibit the proliferation of stimulated CD4+CD25- cells in vitro in mice 
[119]. 
Th e best available marker for Tregs is the expression of transcription factor 
FOXP3, which was fi rst characterized in ‘scurfy’ mice carrying the X chromosom-
al mutation leading to severe autoimmunity. Th ese mice suff ered from a wide spec-
trum of autoimmune diseases. Mutation in the FOXP3 gene coding region leads 
to premature termination of the transcription process, resulting a truncated and 
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biologically inactive protein lacking an NH2 terminus [120]. Th e same mutation 
was earlier described in humans in a FOXP3-like coding sequence called JM2 [12]. 
Patients with mutations in that particular genomic region develop a severe, fatal 
systemic autoimmune disorder called immune dysregulation polyendocrinopathy 
enteropathy X-linked (IPEX) syndrome. In these patients, IPEX causes the enlarge-
ment of secondary lymphoid organs, lymphocyte infi ltration into several organs 
and the manifestation of several immune-mediated diseases, such as autoimmune-
mediated diabetes, eczema and food allergies.
Tregs are divided into naturally occurring CD4+CD25+FOXP3+  Tregs (nTreg), 
that develop in the thymus aft er recognition of high-affi  nity self antigen, and in-
ducible Tregs (iTreg), which are induced from naïve CD4+ T cells following anti-
genic stimulation in the periphery [121-125] (Figure 5). nTregs comprise ~5-10% 
of CD4+ T cells in the peripheral blood [126]. nTregs characteristically express a 
high affi  nity IL-2 receptor α subunit (CD25) on their surface [127]. Unlike eff ector 
T cells that upregulate CD25 upon activation through TCR, nTregs constitutive-
ly express CD25 at very high levels. Th e thymus-induced nTregs characteristical-
ly express cytotoxic lymphocyte activation antigen (CTLA-4), inducible co-stimu-
lator (ICOS), and the glucocorticoid-induced TNF receptor family-related protein 
TNFRSF18 (GITR). Th e observation that forced FOXP3 expression in T cells, leads 
to acquisition of the regulatory potential of these cells underlines the importance 
of FOXP3 for the Treg functioning [121, 128]. nTregs are anergic and they do not 
secrete IL-2 or  proliferate when activated in vitro. In CD4+CD25+ T cells the min-
imal 300-bp proximal promoter does not undergo DNA demethylation of CpG or 
deacetylation of core histones, thus preventing transcription of the IL-2 gene [129]. 
However, nTreg functions are dependent on IL-2 and TGF-β. FOXP3 is essential 
for the diff erentiation and maintenance of Tregs in the periphery, and TGF-β to-
gether with IL-2 is required for FOXP3 induction through SMAD and STAT5 sig-
naling (Figure 5). It should be noted, however, that FOXP3 is also upregulated in 
human CD4+CD25+FOXP3- T cells upon TCR stimulation and thus FOXP3 cannot 
be considered alone as a marker of Tregs [130].
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FIGURE 5. FOXP3 is the master regulator of Tregs. TGF-and IL-2 ligation to their receptors 
leads to the activation of FOXP3 through SMAD3 and STAT5 dependent mechanisms. TCR-
Ag-MHC II interaction leads to the activation of NFATc2, a transcription factor promoting 
FOXP3 activation. High concentrations of FOXP3 inhibit NFATc2 expression, thus providing 
negative feedback. FOXP3 represses the production of IL-2. FOXP3 activates the expression 
of suppressive cytokines TGF- and IL-10 and co-stimulatory molecule CTLA-4, mediating the 
inhibitory signal to the activated T cells.
Th e basic mechanisms of action of Tregs include suppression by inhibitory cy-
tokines, suppression by causing target cell cytolysis or apoptosis, suppression by 
metabolic disruption and suppression by modulation of APC functions. Treg func-
tioning is considered to mainly be mediated through the secretion of inhibitory cy-
tokines TGF-β, IL-10, and recently discovered IL-27 and IL-35 [131]. Th e role of 
IL-27 and IL-35 is not, however, fi rmly established in humans.  
TGF-β has a critical role in maintaining immunological homeostasis. Its role 
in immune regulation in vivo is evident, despite the controversial results from in 
vitro studies [83, 119, 132, 133]. TGF-β down-modulates T-cell responses directly 
and indirectly. It is produced by several immune and non-immune cell types, and it 
acts in both an autocrine and paracrine manner [134, 135]. It can exert its antipro-
liferative eff ects by inhibiting the production of IL-2 and up-regulating cell-cycle 
inhibitors [136]. TGF-β also down-regulates the expression of T-bet and GATA-3, 
thus inhibiting the development of Th 1 and Th 2 subsets of CD4+ T cells [137, 138]. 
Moreover, TGF-β inhibits macrophage activation and their production of pro-in-
fl ammatory cytokines. In addition, TGF-β  down-regulates the expression of MHC 
II class molecules and prevents the maturation of dendritic cells [136]. 
IL-10 is an essential anti-infl ammatory cytokine produced by Tregs, and it has 
anti-infl ammatory and suppressive eff ects on most hematopoietic cells. In addi-
tion, it limits the antigen-presenting capacity of the APCs thus down-modulating 
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the adaptive response generated by CD4+ T cells [139-141]. IL-10 down-regulates 
the expression of co-stimulatory molecules and the expression of pro-infl amma-
tory cytokines produced by the APCs and CD4+ T cells. IL-2 and TNF-alpha pro-
duction by CD4+ T cells is directly inhibited by IL-10 [142]. IL-10 suppresses both 
naïve and memory T cells [143-145]. 
Tregs can also direct their target eff ector T cells to the cytolytic or apoptotic 
pathway by direct cell-cell contact. Cytotoxic activity has been considered to be a 
feature of NK cells and cytotoxic CD8+ T cells, but CD4+ T cells may also exhibit 
cytotoxic activity. Tregs have shown to be able to kill their target cells by granzyme 
B and perforin killing [146]. Th e activity of T cells is also modulated by co-stimu-
latory pathways. CD28 ligation with its ligands CD80 and CD86  co-operates with 
signals mediated by TCR engagement to favor the activation of T cells instead of 
anergy and apoptosis [147]. Two structurally related cell surface molecules are se-
lectively expressed by T cells, namely CTLA-4 and ICOS. Th e expression of these 
molecules is dependent on the activation status of the T cells [148]. CTLA-4 binds 
to the same ligands as CD28, but with a higher affi  nity. CTLA-4 ligation with its 
ligands mediates negative signals to the activated T cells, thus switching them off . 
ICOS ligates members of a diff erent B7 family compared to CD28 or CTLA-4, i.e. 
B7h and B7H. ICOS regulates cytokine production in recently activated T cells, 
and has only a weak eff ect on naïve T cells [149-152]. In humans, it has been shown 
that ICOS favors the diff erentiation of eff ector T cells when operating together with 
an appropriate stimulus, such as anti-CD3 and anti-CD28, whereas it predomi-
nantly supports the diff erentiation of Tregs when co-stimulatory signals are sub-
optimal [153]. 
Several distinct subpopulations of Tregs have been characterized so far in hu-
mans. Several antigen-specifi c Treg cells have been characterized that are induced 
aft er exposure to specifi c exogenous antigens [154]. Stock et al. (2004) suggested 
that there could be a spectrum of iTregs with slightly diff erent characteristics, and 
they reported a Th 1-cell-like Treg population that expressed cytokines IFN-γ, IL-
10, and transcription factors T-bet and Foxp3 in mice [155]. At that time, Th 2-like 
Tregs had already been reported by Akbari et al. in 2002 [154]. 
In addition to CD4+CD25+FOXP3+ Tregs, two other subsets of Tregs have 
been characterized so far, namely Th 3 and Tr1 cells. TGF-β is the cytokine induc-
ing and maintaining the regulatory functions of Th 3 cells [156], while IL-10 is able 
to induce the development and maintain the functions of Tr1 cells [145, 157]. Th 3 
cells mediate their suppression by secreting TGF-β, and Tr1 cells by secreting IL-
10, respectively. Th ese diff erent subsets of Tregs do share some features, such as the 
expression of cell surface molecules CD25, CTLA-4, GITR, CD62L and CD45RBlo 
[158], and the potential to inhibit the proliferation and cytokine production of ef-
fector T cells. Classical nTregs express CD25 at high levels, but Th 3 and Tr1 cells at 
intermediate to low levels. 
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Th 3 cells express the transcription factor FOXP3 upon stimulation, where-
as Tr1 cells do not, suggesting that Tr1 cells are distinct in origin from Th 3, and 
nTregs in particular [157]. Both Th 3 and Tr1 cells have been shown to be able to 
prevent the development of  autoimmune disease [159-161]. Th e function of Th 3 
cells has been associated with the induction of oral tolerance, which has presum-
ably evolved to prevent hypersensitivity reactions to food proteins and bacterial 
antigens present in the normal mucosal fl ora [156]. Continuous exposure to low 
dose antigens eventually leads to the induction of regulatory mechanisms such as 
the emergence of Th 3 cells capable of inhibiting infl ammation by secreting high 
levels of TGF-β [162], whereas high dose  exposure induces anergy and deletion 
[163, 164]. Th 3 cells are particularly important in a variety of disease settings and 
in maintaining tolerance to antigens present in the intestinal tissue [165]. Th 3 cell 
induction is suggested to involve interaction with APCs, DCs in particular [166, 
167]. Intestinal CD103+ cells play a key role in the induction of Foxp3 expressing 
Tregs in oral tolerance induction [168]. 
Tr1 cells can be induced from naïve CD4+ T cells in the periphery by chronic 
exposure to antigens and in the presence of IL-10 secreted by immature dendritic 
cells (iDCs), tolerogenic myeloid DCs and plasmacytoid DCs (pDCs). In mice and 
humans, it has been shown that the induction of Tr1 cells is associated with the de-
velopment of tolerance in transplant settings, and in response to allergens, patho-
gens and tumor antigens [169, 170]. Th e main mechanism for Tr1 cells to mediate 
suppression is the secretion of inhibitory cytokine IL-10. Th e importance of IL-10 
in immune regulation was realized when IL-10 defi cient mice were shown to devel-
op ulcerative colitis [171]. Since the fi rst observation, several studies have associat-
ed IL-10 aberrancies in autoimmune and allergic diseases. Mucosal administration 
of antigens induced tolerance and prevented autoimmune disease in experimen-
tal autoimmune uveitis [172], experimental autoimmune myasthenia gravis [173], 
arthritis in rats [174-176]. Intranasal administration of insulin peptide B: 9-23 in-
duced IL-10 secretion has been shown to protect NOD mice from diabetes [177].
2.4.6 Th 17 cells
Th 17 cells provide protection against bacterial and fungal infections by recruiting 
neutrophils and activating their migration to the site of infection. Th 17 cells se-
crete pre-dominantly IL-17A and IL-17F. Th ese cytokines induce multiple pro-in-
fl ammatory mediators including chemokines, cytokines and metalloproteinases, 
from epithelial and fi broblast cells. Th 17 cells also secrete IL-22, which induces ep-
ithelial cells to produce anti-microbial peptides RegIIIβ and RegIIIγ [178]. IL-17 
producing activated T cells were originally discovered in the mid-1990s. Th e key 
observation was that IL-17 introduced to fi broblasts induced IL-6 and IL-8 pro-
duction and upregulated cell surface expression of the intracellular adhesion mol-
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ecule 1 (ICAM-1). IL-17 transcripts were only detected in stimulated T cells, and 
not in other cell types [179, 180]. In 2005 it was recognized that IL-17 producing T 
helper cells were an independent and separate lineage from Th 1, Th 2 or Treg cells. 
Interestingly, IFN-γ, IL-12 and IL-4 inhibited the induction and development of 
IL-17-producing cells in mice. Accordingly, inhibition of IFN-γ enhanced the de-
velopment of pathogenic IL-17-producing cells. Th us, Harrington et al. considered 
that Th 17 cells have developed via a lineage distinct from the T helper type 1 and 
type 2 lineages [181]. Autoantigen-specifi c and dysregulated Th 1 responses have 
been associated with organ-specifi c autoimmunity. Th e concept of an organ-spe-
cifi c autoimmune response being caused by excessive Th 1 responses was, however, 
challenged by the observation that IL-12p40 knockout mice showed clinical signs 
of EAE. IL-23 is comprised of the p40 subunit of IL-12 but a diff erent p19 subu-
nit, and the absence of IL-23 made symptoms of EAE milder in IL-12p19-defi cient 
mice [182]. When elevated levels of IL-17 were found from the synovial fl uid of pa-
tients with rheumatoid arthritis, it was evident that IL-17 may play a role in human 
autoimmunity [183]. 
Antibodies against IL-17 inhibited chemokine expression in EAE, whereas 
overexpression of IL-17 in the lung epithelium resulted in up-regulation of chem-
okines and lymphocyte infi ltration. Th us, it was reasoned that IL-17 is a critical 
regulator of tissue infl ammation [184]. 
Th 17 cells have been intensively studied during recent years. However, the 
molecular mechanisms directing the induction and development of Th 17 are still 
poorly understood. In vivo studies have revealed that the induction and mainte-
nance of Th 17 cells requires TCR engagement and cytokines TGF-β and IL-6 in 
mice [185, 186]. Originally, IL-23 was thought to play a central role in the induc-
tion of Th 17 cells, but more recently the role of IL-23 has been shown to be the ex-
pansion and stabilization of activated and Th 17-primed T cells, since naïve T cells 
do not have a receptor for the IL-23 cytokine [185]. In the absence of IL-6, Th 17 
cells can still develop, and IL-21 has been demonstrated to be essential for the in-
duction of IL-23R and RORC2, and IL-17 [187].  In synergy with TGF-β, IL-21 has 
been demonstrated to inhibit TGF-β-mediated FOXP3 up-regulation, and the sub-
sequent Treg development of activated naïve T helper cells [188]. Th e observation 
that TGF-β is a critical cytokine for Th 17 cell development was controversial, since 
TGF-β has been considered as an anti-infl ammatory cytokine through its inhibi-
tory eff ect on eff ector T-cell induction. TGF-β induces distinct subpopulations of 
IL-17- and FOXP3-expressing T cells. Th us, TGF-β has a dualistic role on activat-
ed naïve T cells [189]. 
Th e induction and development of Th 17 cells is independent of the transcrip-
tion factors or other signaling molecules that are required for the induction and 
maintenance of Th 1, Th 2, and Treg cells. RORC2 is specifi cally expressed by hu-
man Th 17 cells [190]. In humans TGF-β together with IL-21 and/or IL-6 induc-
es the expression of RORC2 in naïve T cells. (Figure 6) [191]. Up-regulation of 
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FIGURE 6. During the initial activation of CD4+ lymphocytes, continued TGF- and IL-21 and 
IL-6 signaling activates the expression of RORC2 through STAT1/3- and SMAD-dependent 
mechanisms. A high level of IL-6 silences FOXP3 and skews development towards the Th17 
phenotype. RORC2 expression promotes the expression of IL-23R, which is necessary for the 
expansion and stabilization of the Th17 cell population.
RORC2 is dependent on the STAT3 signaling [192]. RORC2 expression leads to 
FOXP3 pathway down-regulation, and Treg development is thus inhibited in acti-
vated naïve T cells. In humans, IL-1β together with IL-6 induce IL-17 response in 
memory T cells [193].
Transcription factor FOXP3 antagonizes the function of Th 17-specifi c RORC2 
by binding physically the RORC2 via the motif encoded by exon 2 of FOXP3. Si-
multaneous expression of FOXP3 and RORC2 has been related to the counter-act-
ing role of IL-6 in FOXP3-mediated inhibition of the IL-17 response [185, 194, 
195]. Th e dynamic balance of Treg cells and Th 17 cells seems to be delicately con-
trolled by several means. In addition to the reciprocal functions of FOXP3 and 
RORC2, the transcription factor RUNX1 is also required for the development of 
both Tregs and Th 17 cells [196, 197]. RORC2 can bind directly to RUNX1, and 
together they can bind to the promoter region of IL-17A, thus enhancing mR-
NA transcription of IL-17A. Moreover, FOXP3, together with RUNX1, can bind 
RORC2 and inhibit IL-17A transcription [196]. RUNX1 mediates the interaction 
between FOXP3 and RORC2 in a cytokine-dependent manner, and mediates the 
balance between activating or repressing activities of the activated CD4+ T cells. 
Another factor in the regulation of the Treg/Th 17 balance is the Aryl hydrocarbon 
receptor (Ahr), and Th 17 cells and iTregs express Ahr at high levels. Ahr is a lig-
and-dependent transcription factor and mediates the eff ects of environmental tox-
ins such as dioxins or FICZ (a UV photoproduct of tryptophan) [198]. Th e Ahr 
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functions in a ligand-specifi c fashion, and it has been reported to support the de-
velopment of Th 17 when FICZ is present, and Treg development when dioxin is 
present [199]. However, the results from diff erent studies have been contradicto-
ry, since another study reported the opposite results for the role of Ahr ligands in 
the induction and development of Treg/Th 17 cells. Experiments with Ahr-defi cient 
animal models have suggested Ahr to be essential for IL-22 expression [199, 200]. 
Th e Th 17 subset of CD4+ T cells provides help for extracellular microbial erad-
ication and fungus eradication. Th 17 cells promote the secretion of a variety of cy-
tokines, metalloproteinases and other infl ammation mediators. Th e recruitment of 
granulocytes is an important function of Th 17 cells [201, 202]. IL-17Ra-defi cient 
mice are more prone to bacterial and fungal infections than wild type littermates. 
Also, the blocking of IL-17 signaling by antibodies directed against the IL-17 re-
ceptors leads to reduced resistance of these animals to bacterial and fungal infec-
tions [203]. In humans, the role of Th 17 cells in the pathogenesis of infectious and 
autoimmune diseases has just begun to be elucidated. 
IL-17-secreting T cells may convert into Th 1-like cells when TGF-β1 is not 
present [204]. Recent reports from animal models indicate that beside nTregs, nat-
ural Th 17 (nTh 17) cells also exist, and they develop in the thymus. nTh 17 cells 
share developmental relationship with FOXP3+ nTregs, showing self-reactivity and 
mucosal homing properties [205].  Th ese natural Th 17 cells also expressed α4β1 
integrins and the chemokine receptor CCR6, and were recruited to the lung, gut 
and liver. Th us, self-ag-specifi c Th 17 cells occur, providing novel insights into the 
immunological mechanisms in organ-specifi c autoimmune diseases such as T1D.
2.5 Risk factors for T1D
2.5.1 Genetic risk
T1D is aggregated in families, and the risk of developing T1D, being inheritable, is 
well known. Th e genetic component of T1D is polygenic, and several loci have so 
far been recognized to contribute to the overall risk of T1D. 
2.5.1.1  HLA polymorphism
Approximately 50% of the total risk is associated within the genomic region con-
taining genes for HLA molecules (Human Leucocyte Antigen, human analog for 
MHC). HLA molecules are expressed on the cell surface. Th e function of HLA 
molecules is to present peptides bound into their peptide binding cleft  and to dis-
play them on the cell surface for recognition by the appropriate T cells. HLA mol-
ecules are divided in two classes that diff er from each other by the structure and 
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the expression signature. HLA class I molecules are ubiquitously expressed. Th ey 
present peptides for the cytotoxic CD8+ T cells. In contrast, the expression of HLA 
class II molecules is restricted to the APCs.
Major determinants of HLA-related T1D risk are HLA class II alleles. HLA-
DQ is a heterodimeric molecule encoded by DQA1 and DQB1 genes. HLA-DQB1 
and HL-DQA1 are highly polymorphic genes, and the variation especially af-
fects the conformation of the peptide-binding groove of these molecules. Th is re-
fl ects in the antigen presentation process, aff ecting the binding affi  nity of peptides 
to HLA-DQA1 and HLA-DQB1 molecules. Th e variation in the antigen presen-
tation properties of diff erent HLA molecules is the explanation for the fact that 
some forms of the molecules are protective against T1D, while others are risk fac-
tors for T1D [206]. HLA-DQB genotyping determines a large proportion of the 
T1D risk, since HLA-DQA1 is in linkage disequilibrium with the HLA-DQB1 lo-
cus. Th e actual risk is, however, more complicated to determine, since other lo-
ci, such as like HLA-DR, modify the overall risk of T1D. Th e highest risk geno-
types for T1D are DQA1*0301-DQB1*0302 and DQA1*0501-DQB1*0201 [207]. 
Some alleles within the HLA-DQ region have a protective eff ect on the HLA-relat-
ed T1D risk. DQB1*0602 has the strongest protective eff ect, whereas DQB1*0301 
and DQB1*0603 have a moderate protective eff ect. 
DQB1*0302 and DQB1*0201 are common in the Finnish general population 
and approximately 40% of Finns have either one of the high risk alleles, while ap-
proximately half of all individuals with one high risk allele have no protective al-
leles.  Th e importance of HLA-DQB1 molecules is underlined by the fact that 90-
95% of the diabetic children carry either the DQB1*0302 allele or the DQB1*0201 
allele, or both.
2.5.1.2 Insulin gene polymorphism
Th e insulin gene promoter is the second gene region  known to contribute the ge-
netic risk of T1D [208].  Th e promoter of the insulin gene contains variable nu-
cleotide tandem repeat polymorphimsms. Polymorphisms within this region have 
been divided into three categories according to the number of 14-15 bp oligonu-
cleotide repeats (VNTR I, II and III) [209]. Th e VNTR I allele has been associated 
with lower insulin expression in the thymus [210-212]. Self-antigens are expressed 
during the negative selection of the lymphocytes in the thymus, under the control 
of  the Aire gene [213]. Reduced insulin expression by the thymic medullary epi-
thelial cells may play a role in T1D through the impaired deletion of autoreactive T 
cells [211, 212], and decreased induction of insulin-specifi c nTregs. 
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2.5.1.3 CTLA-4 gene polymorphism
Polymorphism in the cytotoxic T –lymphocyte antigen-4 gene region in chromo-
some 2 (CTLA-4) was the third gene region found to be associated with the T1D 
risk (IDDM3). CTLA-4 is expressed on the surface of both CD4+ and CD8+ T cells 
aft er the TCR-mediated stimulation [214, 215]. In T-cell activation, CTLA-4 inter-
acts with B7 molecules expressed on the surface of APCs. In resting T cells, the sec-
ond signal needed for activation is delivered through the surface molecule CD28. 
Th e function of CTLA-4 is to down-regulate T-cell responses, and it has been sug-
gested to play a role in the induction and maintenance of peripheral tolerance. Loss 
of function models have shown CTLA-4 to be essential for down-regulation of the 
proliferation of activated T cells [216]. An amino acid-changing nucleotide poly-
morphism has been characterized at position +49 in exon 1 of the CTLA-4 gene 
[217]. Since the fi rst observation of the association of the CTLA-4 gene region and 
T1D by Nistico et al. [218], the +49 A–>  G polymorphism has been associated with 
T1D in several studies [219, 220]. However, considerable ethnic variation exists in 
the association of the CTLA-4 polymorphism and T1D [221]. Th e contribution of 
CTLA-4 to the genetic risk of T1D has been reported in a study in which non-cod-
ing polymorphism of the CTLA-4 promoter was signifi cantly associated with T1D 
[222]. 
2.5.1.4 PTPN22 gene polymorphism
PTPN22 gene product, LYP, is a lymphoid-specifi c protein phosphatase, expressed 
mainly in cells of lymphoidal origin. PTPN22 is notably expressed on CD4+ T cells, 
and it’s function is to negatively regulate transcriptional activity of T cells induced 
by the engagement of T-cell receptor and co-stimulatory molecule CD28 [223]. 
Animal models have associated the dysfunction of PEP, that is homologous to hu-
man LYP, to increased antigen independent proliferation and cytokine secretion 
[224]. 
Th e PTPN22 gene has several polymorphic sites [225]. Polymorphisms in the 
PTPN22 gene region have been associated with several autoimmune diseases, in-
cluding T1D. In 2004 Bottini et al. [226] reported the association of an amino ac-
id-changing nucleotide transition (C to T) at position 1858 with T1D. Since then, 
several reports have confi rmed this association with T1D [227-232], and other au-
toimmune diseases as well. A recent report demonstrated 23 single nucleotide pol-
ymorphisms and 1 deletion insertion polymorphism. In the same study, polymor-
phic site 1858T was confi rmed to be primarily associated with T1D [225].
Th e prevalence of the predisposing allele variant 1858T of the PTPN22 gene 
varies greatly: 15% of the Finnish general population carries the 1858T allele, com-
pared to over 10% of the other Scandinavian populations, 7-8% of the Western 
populations and 2-3% in Italian and Sardinian populations.
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PTPN22 1858T polymorphism is a gain of function mutation. Th e 1858T al-
lele has been shown to have a higher catalytic activity, and this has been associat-
ed with reduced IL-2 secretion and intracellular calcium release [233]. In addition, 
lowered activation of CD4+ memory T cells, decreased expression of CD25 and IL-
10  has been associated with PTPN22 1858T polymorphism [234]. 
2.5.1.5 IFIH1 gene polymorphism
IFIH (interferon induced with helicase C domain 1, also known as MDA5) is an 
intracellular protein recognizing virus RNA and mediating the innate immune re-
sponse. Genome wide association studies have associated gene region containing 
IFIH1, FAP, GCA and KCNh7 genes in chromosome 2 with T1D [235]. Further 
genotyping revealed several variants across the gene region in high linkage disequi-
librium. However, functional properties of IFIH1 gene product suggested IFIH1 
to have possible role in T1D. Recently four low frequency variants were shown to 
be protective for T1D [236]. In  allele specifi c expression analysis, protective hap-
lotype correlated with reduced IFIH1 transcription in interferon-β stimulated PB-
MCs [237]. 
2.5.2 Environmental risk factors
2.5.2.1 Virus infections
T1D is a complex disease with a largely unknown aetiology. Th e disease has a strong 
genetic component. However, despite the fact that risk alleles for T1D are common 
in the Finnish general population, the risk for newborn baby to develop T1D is less 
than 1% [238]. Furthermore, the concordance rate between monozygotic twins for 
developing T1D is 50%. Th us, environmental factors must be involved in trigger-
ing the disease in genetically susceptible individuals. 
Acute virus infections may induce autoimmunity, and the role of viruses has 
been suspected in chronic autoimmune diseases. Virus infections are widely stud-
ied, and yet their role in the pathogenesis process of T1D is still poorly understood. 
Certain viruses have long been associated with T1D. Mumps viruses and congen-
ital rubella viruses are known to be able to induce diabetes in some infected indi-
viduals. However, these viruses have been eradicated from western societies due to 
intensive vaccination programs, and these viruses cannot therefore play a role in 
T1D pathogenesis in developed countries. Studies have occasionally associated cy-
tomegalovirus, Epstein-Barr virus and retroviruses with T1D, but solid evidence 
for their contribution is still lacking [239]. 
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2.5.2.2  Enteroviruses
Enteroviruses were associated with T1D for the fi rst time in 1969 when a patient 
with recent onset T1D was shown to have higher antibody titers against the cox-
sackievirus B4 strain than unaff ected control subjects [240]. Coxsackieviruses iso-
lated from the pancreas of a child who died in ketoacidosis induced diabetes when 
inoculated in susceptible mice, causing hyperglycemia, infi ltration of immune cells 
into the pancreatic tissue and β-cell necrosis [241]. Th e presence of enteroviruses 
has been associated with the appearance of  autoantibodies, suggesting that enter-
oviruses have a possible role in the initiation of autoimmunity. Antibodies against 
enteroviruses were more oft en detected from the serum of subjects who were posi-
tive regarding one or more T1D related autoantibodies, indicating that enteroviral 
infections may have a causal role in the pathogenesis of the disease [242, 243]. Sev-
eral studies have shown children with T1D and prediabetic children to have more 
oft en coxsackievirus RNA or antibodies against coxsackieviruses in their blood cir-
culation [239, 240, 242, 244-248]. Th us, children with T1D or at genetic risk for 
T1D may be more prone to coxsackievirus infections. Th e role of coxsackieviruses 
in the course of T1D is further supported by the reports that show CVB4 to be able 
to infect human  β cells both in vitro [249] and in vivo [250], which may in turn in-
duce β-cell autoimmunity or support it. Recent studies have supported the role of 
enteroviruses in the pathogenesis of T1D. Th e presence of CVB capsid protein vp1 
has been demonstrated in the pancreatic tissue of T1D patients [251]. Moreover, 
enteroviruses have been found in the intestine of T1D patients, whereas the enter-
oviruses were not detected in healthy children [252]. So far, several epidemiologi-
cal studies have repeatedly shown an association between enteroviruses and T1D. 
However, the causal relationship of enterovirus infections and T1D is still unclear.
2.5.2.3 Nutritional factors 
Th e early signs of the initiation of β-cell autoimmunity emerge during the fi rst 
years of life. Despite the strong genetic predisposition to T1D, there is accumulat-
ing evidence supporting the idea that exogenous factors contribute to the initiation 
of β-cell autoimmunity, gradually leading to overt diabetes. Nutrition is an essen-
tial part of the exogenous antigen exposure load, but so far, no specifi c factor has 
been identifi ed as unequivocally related to the risk of initiation of autoimmunity.
2.5.2.4 Th e length of breastfeeding and early exposure to cow’s milk 
  proteins
Th e eff ect of the length of breast feeding has been studied, but the results have been 
controversial. Some studies have shown that a short breastfeeding period in infan-
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cy may be associated with the appearance of β-cell autoimmunity [253, 254]. How-
ever, other studies have indicated that the length of breastfeeding does not contrib-
ute to the individual’s risk of developing β-cell autoimmunity [255, 256] and T1D.
Early exposure to cow’s milk proteins has been considered as one of the pos-
sible factors priming β-cell autoimmunity in genetically predisposed individuals. 
Early exposure to cow’s milk-derived protein has been associated with an elevated 
risk of the initiation of β-cell autoimmunity [253, 254] and T1D [257, 258], where-
as some studies have found no such associations [259, 260]. Th e role of early expo-
sure to cow’s milk-derived proteins in the priming of β-cell autoimmunity is sup-
ported by the observation that when hydrolyzed formula instead one containing 
cow’s milk protein was given to children during the fi rst months of their life, hy-
drolyzed formula signifi cantly reduced the appearance of T1D-associated autoanti-
bodies in those individuals genetically at risk of developing T1D [261]. Interesting-
ly, exposure to bovine insulin in cow’s milk formula induces an immune response 
to bovine insulin, which crossreacts with human insulin, and this primary immu-
nization to insulin, when it takes place during the early months of life, could ex-
plain the link between cow’s milk and T1D. Early exposure to bovine insulin has 
been proposed to be associated with impaired insulin tolerance [262, 263].
2.5.2.5 Wheat proteins
Wheat gluten has been considered as one of the nutritional risk factors for T1D. In-
deed, an association between T1D and celiac disease has been reported [264-266]. 
Gliadin may be the specifi c trigger for subclinical infl ammation in T1D patients. 
When jejunal biopsies from T1D patients and those with celiac disease were stim-
ulated with gliadin, up-regulation of T-cell activation markers CD25 and ICAM-1 
was observed in vitro. Th is up-regulation was not associated with active celiac dis-
ease, but with T1D [267]. Animal models have shown that dietary wheat gluten 
modulates the intestinal immune system, and gluten may therefore also participate 
in the pathogenesis of T1D [268, 269].
2.5.3 Immunological aberrancies in T1D
In health, the immune system delicately balances between the two states: it effi  -
ciently recognizes non-self structures and prevents pathogen invasion, and at the 
same time tolerates self-structures and antigenic structures derived from food 
and commensal bacteria. In T1D, this balance is disturbed and insulin produc-
ing β-cells are progressively destroyed in the pancreas by the body’s own immune 
system. Immune responses against foreign structures are generated by the func-
tion of the innate and adaptive immune systems. Th e innate immune system pro-
vides an immediate response against pathogens based on the recognition of foreign 
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structures by the germ-line-encoded specifi c receptors such as Toll-like receptors 
(TLRs). Th e pathogen structure recognition of the adaptive immune system, how-
ever, is based on usage of variable antigen-specifi c receptors produced by gene 
segment re-arrangements. Th e involvement of adaptive immune responses in the 
pathogenesis of T1D is fi rmly established, as discussed earlier. Th e development of 
T cells specifi c for β-cell structures leads to the generation of pathogenic autoim-
munity targeting insulin-producing β cells. If regulatory mechanisms fail to be in-
itiated, then subtle infl ammation targeting β cells leads to insulitis and eventually 
to overt T1D in some individuals. For the past 15 years, Tregs have been recog-
nized as having a key role in the initiation and maintenance of tolerance, limiting 
harmful autoantigen-specifi c infl ammation processes. Th e diff erentiation of acti-
vated naïve CD4+ and CD8+, as well as the function of fully committed CD4+ and 
CD8+ is tightly controlled by the innate immune system through the cytokine net-
work and cell-cell interaction of APCs and T lymphocytes. Th us, the possible fl aws 
in the regulation of the adaptive immune system may also refl ect aberrancies in the 
innate immune system.
IFN-γ-secreting Th 1 cells prepared from diabetic NOD mice have shown to 
initiate pathogenic events in the pancreatic islets, whereas the transfer of Th 2-type 
cells mainly secreting IL-4 resulted in non-destructive peri-insulitis with no –cell 
death [69]. Infi ltration of type 1 cytokine-secreting lymphocytes is associated with 
the destruction of β cells in the infl amed islets of NOD mice. In parallel, IL-4 se-
cretion was reduced in insulitis-associated mononuclear cells from diabetic female 
NOD mice, suggesting that the β–cell destruction is mediated by cytokines pro-
moting cytotoxicity [270]. In diabetes-prone NOD mice, elevated levels of IL-12, 
IL-18 and IFN-γ were observed, supporting the role of Th 1-type cells in the patho-
genesis of  diabetes [70]. In the same study it was recognized that diabetes-resist-
ant NOD mice did not show up-regulation of Th 1-related cytokines, suggesting 
the Th 1 cytokine milieu to be involved in the pathogenetic processes of autoim-
mune diabetes. Moreover, sustained IL-4 expression in the pancreas of diabetes-
resistant NOD mice suggests that the local cytokine milieu plays a critical role 
in the regulation of local immune responses. According to Foulis et al. [71] over 
40% of the mononuclear cells that infi ltrated the pancreatic islets  of patients with 
T1D expressed IFN-γ, a hallmark cytokine for Th 1-type cells. Increased expres-
sion of IFN-α mRNA was observed from the pancreas biopsy of a newly diagnosed 
T1D patient, supporting the idea that cytotoxic T-cell responses participate in the 
pathogenesis of T1D [72]. When PBMCs from patients with T1D were stimulat-
ed, signifi cantly increased levels of IFN-γ secretion were observed when compared 
to healthy control subjects or patients with Grave’s disease [73]. In contrast, some 
studies have indicated a decreased type 1 response in patients with T1D. Reduced 
levels of  intracellular IFN-γ in CD4+ T cells were reported in the study by Kukreja 
et al., when PBMCs of both recent-onset and long-lasting T1D patients were stim-
ulated with PMA and ionomycin [271]. Antigen-induced IFN-γ secretion has also 
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been observed to be lower in T1D patients than in healthy children when their PB-
MCs were stimulated either with GAD65 or IA-2 antigens [272].
Recently, IL-17-producing T cells have been associated with the pathogene-
sis of T1D. In NOD mouse elevated IL-17 transcript levels were found to correlate 
with the progression of insulitis to diabetes both in the pancreas and blood circu-
lation [273]. In mouse insulinoma cells (MIN6), IL-17 enhances the generation of 
inducible nitric oxide synthase, and elevates the release of NO from the pancreat-
ic β cells. IL-17-induced NO is toxic to β cells, thus driving the β cells to the apop-
totic and necrotic pathway. Th e administration of IL-17-neutralizing antibody re-
duced the release of NO from the pancreatic cells, and diminished the damage of 
insulinoma cells and pancreatic islets induced by activated T cells [274].  More re-
cently, IL-17 neutralization has been demonstrated to prevent T1D development 
in NOD mice. Th e treatment was, however, only eff ective if given aft er the initia-
tion of the autoimmunity process [275]. IL-17 neutralization reduced the islet-spe-
cifi c infl ammatory T-cell infi ltration and increased the proportion of Foxp3+ Tregs 
around the islets, suggesting that Th 17 inhibition leads to the activation of Tregs 
[275]. Th e pathogenic nature of Th 17 cells in T1D was further supported by an ex-
periment in which Th 17 cells transferred diabetes from mouse strain BDC2.5 with 
transgenic islet-cell specifi c TCR to healthy NOD/SCID recipients. In the recipi-
ents, the highly purifi ed Th 17 cells rapidly turned into Th 1-like cells [5]. Moreo-
ver, these cells were able to express Th 1-specifi c transcription factor T-bet and to 
secrete IFN-γ in vitro when stimulated with IL-12. Th ese data indicate substantial 
plasticity of Th 17 cells. Plasticity of fully committed memory T cells may contrib-
ute to the pathogenesis of T1D. 
Th e role of Th 17 cells in the pathogenesis of human T1D is unknown. Mono-
cytes from patients with T1D have shown spontaneous activation of IL-6 and IL-
1, and the monocytes isolated from diabetic patients were able to induce IL-17 
deviation in allogenic memory T cells in vitro [276].  Th is observation indirectly 
supports the idea that IL-17 mediated immunity may be involved in the pathogen-
esis of human T1D. 
Th e aberrancies of Tregs have been associated with T1D in both humans and 
animal studies. In patients with newly-diagnosed T1D, impaired functioning of 
Tregs has been reported [277]. Th e defects were demonstrated as an inability of 
Tregs to inhibit T-cell proliferation, as well as an increased  ratio of IFN-gamma/
IL-10  in the co-cultures of Tregs and T eff ector cells [277]. In contrast, the number 
and function of Tregs was normal in T1D, according to the study by Putnam et al. 
[278]. Evidence from animal models indicates that dynamic changes in the func-
tional capacity of Tregs emerge over time in NOD mice spontaneously develop-
ing autoimmune diabetes. Tregs are present in the infl amed islets in NOD mice, 
and TGF-beta signaling is critical for the control of β-cell destruction [279]. Tregs 
from young NOD mice inhibit autoimmune diabetes, and the eff ect is mediated 
by membrane-bound TGF-β [280]. However, Tregs become functionally defective, 
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i.e. a decline in membrane-bound TGF-β is seen, and they do not regulate β-cell 
autoimmunity when IAA seroconversion occurs in the mouse model. Moreover, 
Treg-associated IL-10 was shown to protect NOD mice from developing diabe-
tes. Th e eff ect of the exogenous IL-10 was potentiated when administered together 
with the immunosuppressive drug rapamycin [281]. Tregs may also lose their abil-
ity to express FOXP3, and begin to secrete infl ammatory cytokines IFN-γ or IL-17. 
If FOXP3 expression is lost, then the eff ector functions may be promoted in the so-
called ex-regulatory T cells. Th ese exFOXP3 cells have been reported to be able to 
transfer diabetes in an animal model [7].
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3 Aims of the study
In T1D, immunological tolerance towards β-cell antigens is broken and the im-
mune system specifi cally destroys insulin-producing β cells in the islets of Langer-
hans of the pancreas. Th e broken peripheral tolerance is probably a manifestation 
of fl aws in immune regulation mechanisms. Th e aim of the studies presented in 
this thesis was to exmine the induction and diff erentiation of T helper cells in T1D, 
and to characterize possible fl aws in the regulation of T-cell responses that may 
contribute to the pathogenesis of T1D. An additional aim was to develop a meth-
odology that could be used for the screening of small molecule entities to enhance 
the function of regulatory T cells in order to identify potential therapeutic candi-
dates for the treatment of autoimmune disorders. 
I Th e aim of the fi rst study was to characterize whether the impaired induction 
of regulatory mechanisms during the activation of T-cell responses is associat-
ed with T1D. 
II Th e aim of the second study was determine whether the T-cell response to 
coxsackievirus, which has been associated with T1D, is aberrant in patients 
with T1D when compared to the healthy subjects with or without a genetic 
risk for T1D.
III In the third study the aim was to characterize whether Th 17 immunity is asso-
ciated with T1D.
IV In the fourth study we aimed to develop a methodology for the screening of 
small molecule entities modulating the dynamic balance between eff ector and 
regulative functions, as measured by the up-regulation of FOXP3.
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4 Subjects and methods
4.1 Subjects
Publication I
For gene expression and cytokine secretion analyses of cultured PBMCs, blood 
samples were taken from 18 recently diagnosed diabetic patients (0-14 days from 
diagnosis; mean age 9.3 years), 11 children who had had T1D for 1 year (mean dis-
ease duration 384 days, SD 36.9, mean age 10.6 years, SD 5.3) and 14 non-diabetic 
children (mean age 8.1 years, SD 3.3) were used.
Th e proliferation inhibition assays were carried out by using blood samples 
from six healthy individuals. Flow cytometry analyses of FOXP3 protein expres-
sion in cultured Th 1-type cells were performed using heparinized blood samples 
from three healthy individuals.
Th e study was approved by the local Ethics Committee. Th e parents and/or 
the study subjects gave their informed consent before the withdrawal of the blood 
sample.
Publication II
A venous blood sample was collected from 15 children with type 1 diabetes (mean 
age 11 years, range 6-17 years, disease duration 1-48 months), and from 13 healthy 
children with HLA risk genotype for T1D (mean age 11 years, range 10-18 years) 
and from 14 children without HLA risk genotype for T1D (mean age 12 years, 
range 10-16 years). Th e HLA risk genotype was defi ned as DQA1* / DQB1* (DR3-
DQ2) and/or DQAB1 (DR4-DQ). All the children without HLA risk genotype 
were also negative for autoantibodies against insulin, GAD and IA-2A. One of the 
children with HLA risk genotype was positive regarding autoantibodies against the 
IA-2A, and another child in this group was positive for insulin autoantibodies. All 
the other children with HLA risk genotype were negative for autoantibodies.
Th e study was approved by the Regional Ethics Committee for Human Re-
search at the Faculty of Sciences of Linköping University in Sweden.
Publication III
Peripheral blood samples were studied from 24 children with type 1 diabetes (mean 
age 8.7 years, SD 4.4, median disease duration of diabetes 12.5 days, range 0-415 
days) and 20 healthy children (mean age 8.2 years, SD 4.4) to  compare Th 17 im-
munity in PBMCs stimulated in vitro and in memory T cells ex vivo. Th e IL-6 lev-
els were also determined from plasma withdrawn by centrifugation from 15 T1D 
patients and 12 healthy children. Both T1D patients and healthy control children 
were genotyped for T1D risk alleles. Genotyping was not performed for three dia-
betic patients or for two healthy control children. Two diabetic children were neg-
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ative for HLA risk alleles, whereas all the remaining diabetic patients carried the 
risk alleles DR3/DQ2 and/or DR4/DQ8. Seven healthy control children were nega-
tive for HLA risk alleles, while 11 were positive for either DR3/DQ2 or DR4/DQ8, 
or both.
For the determination of peripheral blood monocyte activation, frozen PB-
MCs from eight recently diagnosed patients with T1D and eight healthy siblings of 
diabetic children were studied.
Th e study was approved by the Ethics Committees of the participating hospi-
tals. Th e parents gave their informed consent and children aged 10 years or old-
er provided their informed assent before the venous blood samples were collected.
To study the eff ects of pro-infl ammatory cytokines IL-1β, IFN-γ and IL-17 on 
human pancreatic islet cells, seven islet preparations from donated human pancre-
ata were prepared at the Central Laboratory of the Nordic Network for Clinical Is-
let Transplantation in Uppsala. All procedures were approved by the institutional 
Ethics Committees in Sweden and Finland. We also examined the eff ects of pro-in-
fl ammatory cytokines on mouse insulinoma cell lines (MIN6) in three separate in 
vitro experiments.
Publication IV
For the development of the screening methodology we studied CD4+CD25+ cells 
isolated from the peripheral blood of adult (age between 18 and 65 years) volunteer 
blood donors. Th e volunteers were fi rst tested regarding their blood hemoglobin 
levels. An acceptable hemoglobin level of the donor had to be 130g/l or above. Af-
ter the informed consent was received, a venous blood sample up to 300ml was 
withdrawn. Th e study was approved by the local Ethics Committee.
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4.2 Methods
Table 1. Laboratory methods used in this thesis
Cell preparations & Purifi cation of Target Cells Method Publication
PBMC separation from peripheral blood Ficoll gradient centrifugation I, III, IV
PBMC separation from peripheral blood Cell Preparation Tubes™ II
Monocyte depletion Plastic adherence I
Isolation of naive CD4  -cells Magnetic bead technique I
CD4+CD25+ regulatory T cell separation Magnetic micro beads IV
Isolation of monocytes from PBMC Magnetic micro beads IV
Human islet preparation Ficoll gradient centrifugation III
Cell Stimulation Tests   
Cytokine stimulation of PHA activated naive T cells Cell culturing I
Coxsackievirus B4 stimulation of PBMC for 7 days Cell culturing II
CD3+CD28 stimulation of PBMC 40h Cell culturing III
Cytokine stimulation of MIN6 cells  72hCD3 Cell culturing III
Cytokine stimulation of human islets in vitro 72h Cell culturing III
Stimulation and chemical treatment of Treg cells Cell culturing IV
T -cell Suppression Test   
CD4+CD25+ cell co-culture Thymidin incorporation I
Flow Cytometry Analyses   
CD3, CD4, CD25, CD45RA, CD45RO Extracellular staining I
CD4, CD8, CXCR3, CXCR4, CXCR6, CCR2, CCR3, CCR4, CCR5,  Extracellular staining II
CCR7, IL-18R, IL-12R2
CD3, C D4, CCR4, CCR6, TCR/, TCRγ/ Extracellular staining III
CD3, CD4, CD25 Extracellular staining IV
IFN-γ, IL-17 Intracellular staining III
FOXP3 Intranuclear staining I, IV
Cytokine Analyses   
Culture supernatant levels of IL-10 Cytometric Bead Array I
Plasma levels of IL-6 Cytometric Bead Array III
Culture supernatant levels of IFN-γ, IL-5, TGF-1 ELISA I
Culture supernatant levels of IFN-γ ELISA II 
Culture supernatant levels of IL-17 ELISA III
Other Protein Analyses   
Quantitative analysis of T-bet and GATA-3 protein Western blot analysis II
RNA Isolation   
Total RNA isolation from polarized T cells TRIzol extraction method I
Total RNA isolation from virus stimulated PBMCs Filtration technique II, III
mRNA purifi cation from CD4+CD25+ cells Affi nity capture of mRNA IV
Gene Expression Analyses   
T-bet, GATA-3, FOXP3, ICOS and NFATc2,18s RT-PCR & TaqMan I
T-bet, GATA-3, c-maf, IL-4R and IL-12R,18s RT-PCR & TaqMan II
IL-17, RORC2, IL-22, FOXP3, IFN-γ ,T-bet,BCL-2, COX2, NOS2A, SOD2,18s RT-PCR & TaqMan III
FOXP3,B2M RT-PCR & TaqMan IV
Detection of Antibodies   
Detection of GADA & IA-2A autoantibodies from plasma Immunoprecipitation II
Detection of IAA autoantibodies from plasma Radioimmunoassay II
Detection of CVB4 neutralizing antibodies from plasma Microneutralization assay II
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4.2.1 Cell preparations
In studies I, III and IV, PBMCs, were isolated from heparinized blood samples 
by Ficoll gradient centrifugation. Human islets were purifi ed from the pancreatic 
preparations by Ficoll gradient centrifugation.  In study II, the PBMC fraction was 
isolated from heparinized blood samples with Cell Preparation TubesTM accord-
ing to the manufacturer’s instructions (Becton Dickinson). Aft er centrifuge iso-
lation (studies I, III and IV), the cells were washed three times with PBS (Lonza) 
and fi nally re-suspended in RPMI 1640 (Gibco/Life Technologies, Paisley, U.K.) 
supplemented with 5% inactivated human male AB serum (obtained in studies I 
and II from the Finnish Red Cross Blood Transfusion Service, Helsinki, Finland, 
and in study III from Innovative Research, USA), L-glutamine (2mmol/l; Invitro-
gen, Stockholm, Sweden) and gentamicin (25 μg/ml; Sigma-Aldrich, Stockholm, 
Sweden). In study IV, isolated PBMCs were re-suspended aft er the washing steps 
into the X-VIVO15 culture medium (Lonza, Verviers, Belgium). In studies I and 
III, isolated cells were re-suspended at a concentration of 1x106 cells/ml in RP-
MI-1640 culture medium supplemented with inactivated human AB serum (5%), 
L-glutamine (2mmol/l; Invitrogen, Stockholm, Sweden), and gentamicin (25 μg/
ml; Sigma-Aldrich, Stockholm, Sweden). In study IV the isolated PBMC fraction 
was re-suspended in X-VIVO15 culture medium (Lonza) for the further process-
ing. 
4.2.2 Purifi cation of target cells
In study I, plastic adherence was used to deplete monocytes from the PBMC frac-
tion (PBMC at a concentration of 1x106 in a 50 ml plastic cell culture bottle for 1h 
at 37oC in a CO2 incubator). Naïve T cells were purifi ed from the monocyte deplet-
ed PBMC preparations by depleting cells positive for CD45RO with a magnetic 
particle purifi cation technique according to the manufacturer’s instructions (Dy-
nal Corp., Oslo, Norway). In study III, CD4+ memory T cells and monocytes from 
PBMC of T1D patients and healthy children were purifi ed for the gene expression 
analyses. Memory T cells were purifi ed from the freshly isolated PBMC by a mag-
netic separation technique. Firstly, CD4+ T cells were purifi ed using a CD4 Mul-
tisort Kit (Miltenyi). Naïve T cells positive for the CD45RA isoform were then 
depleted using CD45RA microbeads according to the manufacturer’s instructions 
(Miltenyi Corp., Bergisch Gladbach, Germany). CD45RO+ memory T cells were 
lysed in Qiagen RLT Buff er for RT-qPCR analysis. Th e purity of the isolated memo-
ry T cells was assessed by fl ow cytometry. Th e memory T cell purity of the prepara-
tions was constantly greater than 90%. Monocytes from frozen and thawed PBMC 
were isolated with a magnetic purifi cation technique (Miltenyi). Monocyte Isola-
tion Kit II and LS columns were used according to the manufacturer’s instructions 
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(Miltenyi). Th e purity of isolated CD14+ monocytes was assessed by fl ow cytome-
try. Aft er the isolation of CD4+ memory T cells and monocytes, cells were washed 
with PBS and lysed with RLT buff er (Qiagen), supplemented with 1% 2-mercap-
toethanol. Th e lysate was stored at -80oC prior to RNA extraction. 
In study IV, CD4+CD25+ cells were purifi ed from PBMC fractions by using the 
MACS (Miltenyi Corp., Bergisch Gladbach, Germany) magnetic separation tech-
nique. CD4+ cells were negatively selected by incubating PBMCs with magnetic 
particles coated with antibodies targeting cells other than CD4+ T helper cells and 
collecting the fl owthrough fraction. Negatively-selected CD4+ cells were washed 
with 0.5% BSA in PBS with EDTA. Cells were briefl y spun down and incubated for 
20 minutes at 4oC with magnetic microbeads coated with antibodies targeting the 
CD25 molecule. CD4+CD25- cells were fi rst washed out from the column attached 
to a magnetic stand. Th en the column was removed from the stand and placed in a 
15 ml Falcon tube and the magnetically labeled CD4+CD25+ cells were eluted from 
the column with the elution buff er according to the manufacturer’s instructions. 
Th e purity of the eluted CD4+CD25+ cells was confi rmed by fl ow cytometry.
4.2.3 Cell culture methods
Stimulation of CD45RA+ T cells in type 1 or type 2 cytokine conditions (I). CD45RA+ 
T cells were stimulated with PHA and type 1 or type 2 cytokines in RPMI-1640 
culture medium (Invitrogen, Paisley, UK) supplemented with heat-inactivated hu-
man AB serum (5%), L-glutamine (2mmol/l; Invitrogen, Stockholm, Sweden), and 
gentamicin (25 μg/ml; Sigma-Aldrich, Stockholm, Sweden). For type 1 stimula-
tions, 200 pg/ml IL-12  (Sigma)  and 50 ng/ml anti-IL-4 (BD Pharmingen, San Di-
ego, CA, USA) were used, and for type 2 stimulations, 400 pg/ml IL-4 (Sigma) and 
anti-IL-12  were used (1 μg/ml, Serotec, Oxford, UK). Aft er culturing cells for 72h, 
cells were harvested and homogenized in the TRIzol reagent (Invitrogen). Stimu-
lation of PBMCs with coxsackievirus B4 strain (II). PBMCs were stimulated by cul-
turing 2x106 cells per well in a 24 well cell culturing plate. Coxsackievirus B4 strain 
(1μg/ml; obtained from the American Type Culture Collection, Manassas, VA) was 
used for the stimulation of isolated PBMCs. Viruses were inactivated by incubating 
them at 56°C for 30 min. IL-2 (BD PharMingen, Stockholm, Sweden) was added 
to the cell cultures on the third day at the concetration of 32 pg/ml. On the seventh 
day of the cell culture, supernatants were collected and stored at -70°C for later cy-
tokine analyses. For mRNA, Western blot and fl ow cytometry analyses cells were 
collected on day seven. For mRNA analysis, cells were collected and lysed with the 
lysis buff er of a total RNA purifi cation kit (Sigma-Aldrich, St.Louis, MO, USA). 
Lysed cells were stored at -70°C until use. Cells for Western blot analyses were col-
lected and stored in liquid nitrogen until use. PBMC stimulation with anti-CD3 and 
anti-CD28 (III). T-cell stimulations were performed by culturing 2 x 105 PBMCs in 
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a total volume of 200μl for 40 h as three replicates in 96-well round-bottom cultur-
ing plates (NUNC) pre-coated with anti-CD3 antibody (50 μl of anti-CD3 at 5μg/
ml in PBS) (BD Pharmingen) and in the presence of soluble anti-CD28 antibody at 
the concentration of 0.5μg/ml (BD Pharmingen). Aft er the incubation, cells were 
collected and lysed in Qiagen RLT lysis buff er for RT-qPCR analyses. Prior to col-
lecting cells, supernatants were collected for cytokine detection. Stimulation of is-
let cells (III). Batches of islets were incubated in non-adherent 24-well plates for 24 
h or 72 h in RPMI 1640 medium (Gibco) supplemented with antibiotics and 10% 
FCS (Lonza) and treated without (as negative control) or with one or more of fol-
lowing recombinant human cytokines: IL-17 (100 ng/ml, eBioscience), IL-1β (5 
ng/ml, PeproTech) and IFN-γ (50 ng/ml, PeproTech). MIN6 cells (a mouse insuli-
noma cell line) were cultured in 12-well tissue culture plates with or without glass 
coverslips in D-MEM medium (4.5 g/l glucose, Lonza) supplemented with antibi-
otics, beta-mercaptoethanol (0.25 μmol, Gibco) and 15% FCS (Lonza). MIN6 cells 
were treated with cytokines similarly to human islets. Stimulation of Tregs (IV). Th e 
cell attachment test was performed by culturing 4000 CD4+CD25+ and CD4+CD25- 
cells on plates with or without anti-CD3 coating (BD Pharmingen, San Diego, Cali-
fornia, USA). U-bottomed 96-well culture plates (NUNC, Roskilde, Denmark, Cat.
No. 163320) were incubated with anti-CD3 at the concentration of 5μg/ml in PBS 
(30 μl/well) for 4 hours at 37oC in the presence of 5% of CO2. Aft er the coating step, 
cell culture plates were washed three times with 100μl of PBS. Th e cells were then 
spread onto the plate and cultured for 16 h at 37oC and in 5% CO2 in the follow-
ing  test conditions: cells in culture medium, cells incubated in wells with plate-
bound anti-CD3; and cells incubated in wells with plate-bound anti-CD3 and sol-
uble anti-CD28 (BD Pharmingen, San Diego, California, USA, Cat.No. 555725) at 
the concentration of 5μg/ml and TGF-β1 (R&D Systems, Minneapolis, USA, Cat.
No. 240-B) at the concentration of 20 ng/ml in a total volume of 100μl of X-VI-
VO15 culture medium (Lonza, Verviers, Belgium). In the pilot chemical screening 
of study IV, CD4+CD25+ cells were prepared as previously described and incubat-
ed at + 37oC for 72 h with diff erent members of the Spectrum Collection chemi-
cal library (MicroSource Inc., CT, USA) at the concentration of 1 μM. In the pilot 
screen, we performed the experiment in two 96-well chemical plates each contain-
ing 80 diff erent members chosen randomly from the chemical library. As a positive 
control CD4+CD25+ cells were cultured with plate-bound anti-CD3 and soluble an-
ti-CD28 at the concentration of 5μg/ml and TGF-β1 at the concentration of 20 ng/
ml for 72 h. Cells were incubated for 72 h and mRNA samples were collected. Th e 
inter-individual variation in the response to the compound was analyzed by using 
CD4+CD25+ cells from six diff erent donors. Th e dose-response curve was tested for 
anti-CD3-stimulated and phenylbutazone-treated CD4+CD25+ cells at concentra-
tions of 0.1 μM, 1.0 μM and 10 μM by using CD4+CD25+ cells from two diff erent 
donors.  Th roughout study IV, mRNA samples were collected similarly aft er the 
incubation. First, the culture supernatants were gently removed with a Biomek FX 
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(Beckman Coulter, CA, USA) at the speed of 5 μl/second aft er centrifugation of the 
culture plates for 5 minutes at 800*g. Th e cells were then lysed with 50 μl of mR-
NA Lysis/Binding buff er of the Bio-Nobile QuickPick™ mRNA kit (Bio-Nobile Ltd., 
Turku, Finland) and stored at -80oC prior to mRNA extraction.
4.2.4 T-cell suppression assay
In study I, the suppressive capacity of CD4+CD25+ cells generated upon stimula-
tion of naïve T cells with the type 1 condition was tested with the thymidin incor-
poration assay. Briefl y, CD4+CD25+ and CD4+CD25- eff ector cells were separated 
from T cells stimulated with type 1 cytokine conditions for 72 h using the magnet-
ic bead separation technique MACS (Miltenyi Corp., Bergisch Gladbach, Germa-
ny). Fift y thousand CD4+CD25- cells were stimulated  with soluble anti-CD3 (5 μg/
ml) and anti-CD28 (5 μg/ml) in the presence or absence of  purifi ed CD4+CD25+ 
cells at a ratio of 1:1 for 48 h. Tritiated thymidin was then added into the culture 
wells and the plates were incubated for 18h and harvested on a glass fi bre mat with 
a Tomtec 93 Mach III manual cell culture harvester (Tomtec, Orange, CT, USA). 
Th e incorporated radioactivity was measured with a Micro-Beta scintillation coun-
ter (Wallac, Turku, Finland). 
4.2.5 Flow cytometry analyses 
In study I, fl ow cytometry was used for the analysis of cell surface molecules CD3, 
CD4, CD25 and the intranuclear molecule FOXP3. T cells stimulated in a type 1 cy-
tokine environment for 72 h were harvested and fi xed with 1% paraformaldehyde 
and 0.05% Tween-20 overnight at 4oC, and then treated twice with DNAse I (Ro-
che Diagnostics, Mannheim, Germany). Th e cells were then incubated with mon-
oclonal mouse-anti-human FOXP3 (clone 150D/E4) (a gift  from Alison Banham, 
University of Oxford, UK), and Alexa-Fluor 488® goat anti-mouse IgG (Invitro-
gen). Intracellular IFN-γ was stained using mAb PE mouse anti-human IFN-γ (BD 
Pharmingen). Aft er the staining of intracellular and nuclear molecules, cell surface 
antigens were stained. Th e cells were then incubated with PerCP anti-human CD4 
(BD Pharmingen) and APC anti-human CD25 (BD Pharmingen) for 20 minutes 
at room temperature and washed with 0,5% BSA in PBS. Binding of antibodies to 
their target molecules was analyzed with FACSCaliburTM instrumentation and Cel-
lQuestTM soft ware (Becton Dickinson, San Jose, CA, USA) was used to analyze 
the stained cells. In study II, approximately 300,000 cells were stained with APC-
anti-CD4, PCP-anti-CD8, PE anti-IL-12R-β2 chain, PE-anti-CCR4, FITC- anti-
CCR5 (BD PharMingen, San Jose ,CA), FITC-anti-CXCR4, FITC-anti-CXCR3, 
PE-anti-IL-18R, FITC-anti-CCR7, PE-anti-CCR2, FITC-anti-CCR3, and PE-anti-
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CXCR6 (R&D Systems, Minneapolis, MN). Appropriate isotype controls were used 
to determine the specifi c binding for each fl uorescent channel. Cells were incubat-
ed with conjugated antibodies for 30 min and then washed with PBS (Medicago, 
Uppsala, Sweden) supplemented with 0.5% BSA (Difco Laboratories, Detroit, MI). 
Aft er a short centrifugation the cells were resuspended in 160 μl PBS supplement-
ed with 0.5% BSA. Th e labeled cells were analyzed with four-color fl ow cytome-
try using FACSCalibur and CellQuest soft ware (Becton Dickinson, San Jose, CA). 
In study III, intracellular cytokines IFN-γ and IL-17 were analyzed in addition 
to the cell surface markers CD3, CD4, CCR4, CCR6, TCRα/β, and TCRγ/δ. Prior 
to harvesting cells for staining, GolgiStop reagent (BD Biosciences) was added for 
at least the last 4 h of T-cell activation of PBMCs. Collected PBMCs were washed 
once with 0.5% BSA in PBS and briefl y centrifuged. Th e PBMCs were stained for 
surface antigens using anti-CD4-FITC (Becton Dickinson), anti-CCR4-PE (BD 
Pharmingen), anti-CCR6-PE (BD Pharmingen), anti-TCR/-FITC (Becton 
Dickinson), and anti-TCRγ/δ-FITC (Becton Dickinson). Th e cells were then fi xed 
and permeabilized using the Cytofi x/Cytoperm Plus Fixation and Permeabilization 
Kit (BD Biosciences). Intracellular IFN-γ and IL-17 were stained with anti-IFN-γ-
PE (Becton Dickinson) and anti-IL-17-Alexa 647nm (eBioscience). Appropriate 
isotype controls were used to determine specifi c binding for each fl uorescent chan-
nel: IgG1-FITC (Becton Dickinson), IgG1-PE (Becton Dickinson) and IgG1-Al-
exa 647nm (eBioscience). In study IV, the purity of the isolated CD4+CD25+ cells 
was analyzed by fl ow cytometry. Extracellular markers CD3, CD4, and CD25 were 
stained and detected similarly to study I.
4.2.6 β-cell viability and apoptosis assay
In study III, the proportion of necrotic and apoptotic cells was determined by nu-
clear double staining with 5 μg/ml Hoechst 33342 (HO, Sigma) and 5 μg/ml pro-
pidium iodide (PI, Sigma). Aft er the incubation, the cells were exposed to the dyes 
for 30 min at 37ºC, and then washed with PBS. Th e human islet cells were further 
dissociated with 0.05% trypsin and 0.02% EDTA and centrifuged to the slides be-
fore fi xation. However, MIN6 cells on cover slips were directly fi xed with 4% para-
formaldehyde (PFA) for 20 min at room temperature. A fl uorescence microscope 
was used to observe the staining of the cells and photographs were taken for lat-
er counting. 
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4.2.7 Cytokine analyses
In studies I and II, an in-house ELISA was used to analyze IFN-γ concentrations 
in the culture supernatants. In brief, Maxisorb plates (Nunc, Roskilde, Denmark) 
were coated with monoclonal anti-human IFN-γ (M-700 A; Endogen, Woburn, 
MA) at the concentration of 2 μg/ml (50μl/well). Plates were incubated overnight 
at +4°C, and washed with PBS-Tween. Plates were blocked in PBS containing 1% 
BSA for 30 min. Recombinant human IFN-γ (Pharmingen, San Diego, CA) was 
used to prepare a standard curve. Next, 100μl of supernatant samples and stand-
ards were added onto plates and incubated for 2 h. Th e plates were then washed 
with PBS-Tween and biotinylated monoclonal anti-human IFN-γ (Endogen) was 
added at the concentration of 0.5 μg/ml (50 μl/well). Aft er incubation for 90 min-
utes, a streptavidin-alkaline phosphatase complex was added. For the color devel-
opment, p-nitrophenyl phosphate (Medix, Kauniainen, Finland) was added and 
the plates were analyzed using a plate reader. In study I, a commercially available 
ELISA kit was used to assess the culture supernatant levels of IL-5 and TGF-β1 in 
concordance with the manufacturer’s instructions (R&D Systems). A commercial-
ly available CBA kit (Cytometric Bead Array) was used to analyze the IL-10 levels 
of the culture supernatants in study I and IL-6 levels of the plasma in the study III. 
 
4.2.8 Western blot analyses for T-bet and GATA-3
In study II, protein levels of transcription factors T-bet and GATA-3 were ana-
lyzed using the Western blot technique. First, total protein was isolated from the 
CVB4-stimulated PBMCs and 5 μg of total protein was run on a 10% SDS-poly-
acrylamide gel (Bio-Rad Laboratories, Hercules, CA). Th en the gel was blotted on-
to a polyvinylidene difl uoride nitrocellulose blotting membrane (Amersham Bio-
sciences UK, Buckinghamshire, U.K.). Th e membrane was blocked by incubating 
it for 1 h in PBS-Tween (Medicago) supplemented with 5% nonfat dried milk (Bio-
Rad Laboratories) and 0.2% sodium fl uoride (Merck, Damstadt, Germany). Anti-
bodies against T-bet and GATA-3 (Both antibodies were obtained from the San-
ta-Cruz Biotechnology, CA, USA) were then added onto the membrane as 1:1000 
dilutions followed by washes. Th e membrane was subsequently incubated with a 
1:15000 dilution of the rabbit anti-mouse IgG-conjugated horseradish peroxidase 
(Bio-Rad laboratories). Th e membrane was blocked again as previously described. 
GAPDH antibody (fi nal dilution 1:1,000; Santa Cruz Biotechnology) was then in-
cubated with the membrane. Th e membrane was washed a few times and incubat-
ed with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (fi nal di-
lution 1:15,000; Bio-Rad Laboratories). Th e proteins were detected with an ECL 
Plus kit (Amersham Biosciences) and chemiluminescence fi lms (Amersham Bio-
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sciences). Th e immunoblots were quantitated by densiometric scanning (Gel-PRO 
analyzer; Media Cybernetics, Silver Spring, MD).
4.2.9 RNA isolation methods for RT-qPCR
In study I, the chloroform/phenol extraction method TRIzol (Invitrogen) was used 
according to the manufacturer’s instructions for the isolation of the total RNA from 
the stimulated T-cell cultures. In studies II and III, a column fi ltration technique 
was used for the isolation of total RNA from stimulated cell cultures and from the 
isolated monocytes. In study II, total RNA was isolated from the samples by using 
a Genelute total RNA isolation kit (Sigma-Aldrich, St. Louis, MO). In study III, to-
tal RNA from the cultured human PBMCs and CD4+ memory T cells and human β 
cells was isolated with a Qiagen RNeasy Mini kit with the on-column DNase I treat-
ment option of the RNA isolation kit. From the purifi ed human monocytes, total 
RNA was isolated using a Qiagen RNeasy Micro Kit with the on-column DNase I 
option. In study IV, mRNA was isolated from stimulated CD4+CD25+ cells with 
QuickPick™ mRNA chemistry in accordance with the manufacturer’s instructions 
(Bio-Nobile Ltd, Turku, Finland). Binding of mRNA molecules to oligo-dT-coated 
magnetic particles took place during a 10-min incubation in a shaker at the revs of 
500 rpm, which was followed by two washes with wash buff er A in a volume of 100 
μl and one wash with the wash buff er B. Finally, particles were eluted in 100 μl of 
Elution Buff er provided with the kit. All the particle transfers were carried out with 
a Magro 8-M automated robotic workstation (Bio-Nobile Ltd, Turku, Finland). 
4.2.10 Reverse transcription of the isolated RNA
In studies I and II, isolated total RNA was subjected to additional DNase I (Roche 
Diagnostics, Mannheim, Germany) treatment to eliminate genomic DNA contam-
ination from the sample. In studies I-III, fi rst strand cDNA synthesis was primed 
using the random hexamer option of the High Capacity cDNA Archive kit accord-
ing to manufacturer’s instructions (Applied Biosystems, California, USA). In study 
IV, we designed reverse transcription utilizing solid phase elution of the mRNA. 
mRNA synthesis was primed using the oligo-dT priming option of the Transcrip-
tor kit (Roche Corporation, Mannheim, Germany, Cat. No. 4379012), following 
the guidelines given by the manufacturer of the kit, with the exception that the 
concentration of oligo-dT was two times higher in the fi nal reaction mix. Supple-
mental oligo-dT(15) was obtained from the Roche Corporation. (Cat. No.814270). 
Magnetic particles with the bound mRNA were spun slightly down (100*g for 1 
minute) and a Biomek FX robotic workstation was used to remove the excess elu-
tion buff er. Next, 5 μl of elution buff er suspension containing the mRNA-magnet-
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ic particle complexes was applied to the reverse transcription reaction already pi-
petted into the 96-well PCR. Th e RT reaction was performed in an MJ-200 thermal 
PCR cycler using Th ermo-Fast 96 Skirted PCR plates (Cat. No.AB-0800-L, Abgene, 
Epsom, UK). Oligo-dT-primed reactions were incubated at +55˚C for 55 min and 
at +85˚C for 5 min. Th e cDNA was stored at -20˚C until use. 
4.2.11 Quantitative PCR
In studies I-IV, readily designed and optimized TaqMan Gene Expression assays 
spanning over the exon-exon boundaries were used for the real time detection of 
the target gene cDNA amplifi cation (see Table 1. for a list of genes). In studies I-
III, an assay specifi c for the ribosomal 18s subunit was used as an endogenous con-
trol for the normalisation of the amount of RNA in the real time PCR. In study IV, 
a VIC-labeled assay specifi c for beta-2-microglobulin was used as an endogenous 
control. Assay for the amplifi cation of beta-2-microglobulin was designed to span 
over exon-exon boundary. In studies I, II and IV, real time PCR was carried out 
according to the manufacturer’s protocols using a TaqMan Universal PCR master 
mix with AMPerase UNG (Applied Biosystems). In study III, a TaqMan Fast Mas-
ter Mix with no AMPerase UNG was used for the sequence-specifi c amplifi cation. 
In studies I and II, an ABI Prism 7700 sequence detector instrumentation (Ap-
plied Biosystems) was used for signal detection, whereas a StepOne Plus real time 
PCR instrument (Applied Biosystems) was used for the detection in study III and 
an ABI 7900 HT real time PCR instrument was used for the detection in study IV. 
For the estimation of the original copy number at the beginning of each reaction, 
a comparative threshold cycle method (ΔΔCt –method) was used in studies I-IV. 
Th e quantitative value obtained from the TaqMan run is a threshold cycle Ct, indi-
cating the number of PCR cycles at which the amount of an amplifi ed target mole-
cule exceeds a predefi ned fl uorescence threshold. Th e diff erence value (ΔCt) is the 
normalised quantitative value of the expression level of the target gene achieved by 
subtracting the Ct value of the housekeeping gene from the Ct value of the target 
gene. Control cDNA pool (calibrator) was considered as an inter-assay standard, to 
which the normalised samples were compared. In studies I-III, calculations for the 
relative gene expression are expressed as follows: ΔΔCt(sample 1) =ΔCt(sample 1) 
− ΔCt(calibrator). Th e diff erence in expression level between the sample and the 
calibrator is given by the formula: 2(−ΔΔCt). For graphical reasons relative expres-
sion levels were multiplied by a constant factor. Th e calibrator was made by prepar-
ing cDNA from RNA derived from PHA-stimulated PBMCs of healthy donors. In 
study IV, the mean ΔCt value of the anti-CD3 stimulated CD4+CD25+ culture wells 
(n=4 per plate) was considered as a reference within each plate. Relative FOXP3 ex-
pression levels of the anti-CD3 stimulated and chemical treated CD4+CD25+ cells 
were calculated with the formula: relative expression of 
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sample 1 =2-[ΔCt(sample1) – ΔCt (mean anti-CD3)].
4.2.12 Detection of antibodies
In study II, autoantibody concentrations of GAD and IA-2A in plasma were an-
alyzed by immunoprecipitation as previously described [282, 283]. Positivity for 
GAD and tyrosine phosphatase autoantibodies was determined as antibody levels 
above the 98th percentile. Th e Diabetes Autoantibody Standardization Program 
2003 was used to set the specifi city and sensitivity levels. For the  GAD autoanti-
body assay, the specifi city was 98% and the sensitivity was 78%, and for the tyro-
sine phosphatase autoantibody assay, the specifi city was 100% and the sensitivity 
was 48%. 
CVB4 antibodies were determined by a microneutralization assay in green 
monkey kidney cells. First, 75 μl of the virus, corresponding to 30–300 TCID_50 
units was mixed with 75 μl fourfold dilution of plasma specimens on microtiter 
plates (96-well Nunclon Microtest plates). Th e plates were incubated for 1 h at 36°C 
and then left  overnight at 4°C. Th e next day, 30,000 cells were added to each well, 
and the plates were incubated at 36°C for 6 days before staining with crystal violet. 
Th e highest dilution with complete inhibition of the virus-induced cytopathic ef-
fect was considered as the end point titer.
4.2.13 Statistical analyses
In studies I and II, groupwise comparisons were performed using the non-para-
metric Kruskal-Wallis test. In studies I-III, pairwise comparisons were carried out 
by using the non-parametric Mann-Whitney U-test. Variable correlations were an-
alyzed in studies I-IV with the Spearman rank correlation test. In study III, ex-
pression levels of the target gene mRNA in memory CD4+cells were compared 
between the two groups with the two-tailed Fisher’s exact test. Th e changes be-
tween untreated and cytokine treated human islets or MIN6 cells were analyzed 
with a paired t-test. In study IV, the changes in the expression level of FOXP3 up-
on chemical treatment of stimulated CD4+CD25+ cells were analyzed with the Wil-
coxon Signed Rank test. Linear regression was used to analyze the relationship be-
tween variables in study IV. Statistical analyses were performed using Graph Pad 
Prism 4 soft ware (San Diego, CA, USA).
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5 Results and discussion
5.1 No diff erences in factors directing T-cell 
 polarization in T1D
Naïve T cells from recently diagnosed type 1 patients, patients who had had T1D 
for one year and healthy control children were stimulated with phytohemagglu-
tin (PHA) and polarized towards either the type 1 or type 2 phenotype with IL-
12 or IL-4 cytokines, and neutralizing antibodies against IL-4 or IL-12 respective-
ly. Higher IFN-γ secretion was seen in cells stimulated in the type 1 environment 
than in those stimulated in the type 2 environment (median values 296 ng/ml ver-
sus 0.3ng/ml). Higher IL-5 secretion was seen in cells stimulated in the type 2 en-
vironment than in those cells stimulated in the type 1 environment (median values 
330 pg/ml versus 32 pg/ml). IFN-γ, IL-5, IL-10, and TGF-β1 secretion did not dif-
fer between diabetics and healthy controls.
Relative mRNA expression levels of Th 1 and Th 2 diff erentiation directing 
transcription factors in respective cell cultures indicated successful polarization. 
In the type 1 culturing condition, Th 1-specifi c transcription factor T-bet was ex-
pressed at higher levels when compared to type 2 cell cultures (Figure 7. panel A 
vs. B). No diff erence in the expression of T-bet was observed between patients and 
healthy control subjects in T cells cultured in type 1 or in type 2 environments (Fig-
ure 7, panels A and B). In type 2 cell culture conditions, GATA-3 was expressed at 
a higher level when compared to type 1 cell culture conditions, as shown in Figure 
7 (Panel C vs. D). No diff erence was observed between patients and healthy control 
children in GATA-3 expression in T cells cultured in the type 2 conditions (Fig-
ure7, panel D). 
Prior to study, we studied the kinetics of the transcription factors T-bet, GA-
TA-3 and FOXP3 in cell cultures with type 1 and type 2 cytokine environment. We 
chose the incubation time of 72h due to the observation that all three transcrip-
tion factors showed maximal mRNA expression by the third day of cytokine stim-
ulation.
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  A type 1 conditions  B type 2 conditions
  C  D 
FIGURE 7.  mRNA expression levels of T-bet and GATA-3 in T cells cultured in type 1 (panels A 
and C) or type 2 (panels B and D) environment from patients with recently diagnosed T1D 
(RD), patients with long-lasting T1D (1 year), and in healthy controls (control). No differ-
ence in factors directing Th1 and Th2 polarization was seen when T1D patients were com-
pared with healthy children. Data are shown as box plots (median, 25% and 75% quartile 
with whiskers denoting maximal and minimal data points) and expressed as arbitrary rela-
tive units.
T1D is has been considered to be an organ-specifi c autoimmune disease mediat-
ed by uncontrolled Th 1 responses. Animal models of T1D have shown increased 
IFN-γ levels to be associated with the infl ammation process in the pancreas. How-
ever, we did not observe up-regulation of factors related to Th 1-type responses in 
patients with T1D, when naïve T cells were activated with PHA and stimulated 
with IL-12 and anti-IL-4. Patients with T1D and healthy control children similarily 
up-regulated the Th 1-related factors T-bet and IFN-γ upon stimulation, indicating 
normal T-cell activation in T1D patients. No diff erence in the expression of Th 2-
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related markers GATA-3 and IL-5 was observed in type 1 or type 2 cells generated 
in vitro, further supporting the normal T-cell activation in T1D patients.  
5.2 Impaired up-regulation of Treg-associated genes in 
 T cells of T1D patients stimulated in a type 1 
 cytokine environment 
Th e T cells of patients with newly diagnosed T1D stimulated in a type 1 cytokine 
environment showed decreased expression of FOXP3 when compared to healthy 
controls, with median values of 22.2 versus 38.6 (Figure 8, panel B). A similar trend 
was seen when comparing patients with longer duration T1D and healthy control 
children (Figure 8, panel B). Th e diff erences in FOXP3 expression between the pa-
tients with newly diagnosed T1D, patients with longer-duration T1D, and healthy 
control children were already seen in naïve T cells, the median values being 3.8 ver-
sus 9.8 versus 8.0 respectively (Figure 8, panel A).
B A 
FIGURE 8.   mRNA expression levels of FOXP3 (panels A and B) in naïve T cells (panel A),  and 
in T cells cultured in a type 1 environment from patients with recently diagnosed T1D, pa-
tients with long-lasting T1D and in healthy controls. The expression of FOXP3 differed be-
tween the three groups in naïve T-cells and in T cells activated in a type 1 cytokine environ-
ment (p=0.003 and p=0.02 Kruskall-Wallis test). Signifi cant p-values for comparisons between 
two groups are shown in the fi gure. Data are shown as box plots (median, 25% and 75% 
quartile with whiskers denoting maximal and minimal data points) and expressed as arbi-
trary relative units.
                                naive T cells                                                                type 1 conditions
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In T cells stimulated in a type 1 cytokine environment, inducible co-stimula-
tor (ICOS) showed higher expression in patients with recent-onset T1D than in 
healthy children, the median values being 50.8 versus 91.6 (p=0.001). No diff erence 
in ICOS expression was observed between patients with longer-duration T1D and 
healthy children. Higher expression of NFATc2 was observed in type 1 cytokine 
stimulated T cells of healthy control children than in the T cells of patients with 
recent-onset T1D, with median values of 7.8 versus 3.8 (p=0.02). NFATc2 showed 
no diff erence in the expression in T cells stimulated by type 1 cytokines between 
healthy control children and patients with T1D of prolonged duration, with medi-
an values 7.8 versus 5.1. Between 3-8% of CD4+CD25high gated cells showed FOXP3 
protein expression in a subgroup of T cells stimulated in a type 1 cytokine environ-
ment (Figure 9).
Th e CD4+CD25+ cells isolated from the T cells stimulated in a type 1 cytokine 
environment showed inhibition of proliferation in one of six individuals studied, 
when co-cultures of CD4+CD25+ and CD4+CD25- cells mixed at ratio 1:1 were 
stimulated with mitogen.
FOXP3 is a signature transcription factor for Tregs, which have a central role 
supporting peripheral tolerance towards the body’s own structures. Our observa-
tion of decreased FOXP3 in diabetic patients in a type 1 cytokine milieu suggests 
that mechanisms mediating the induction and maintenance of peripheral toler-
FIGURE 9. Flow cytometry analysis of  FOXP3 in CD4+CD25hi cells generated from naïve T cells in 
a type 1 cytokine stimulation for 72h. 
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ance may be disrupted by the cytotoxic response associated with tissue destruc-
tion in the pancreas. Tregs have been considered to mediate the anti-infl ammato-
ry response by inhibiting the proliferation of eff ector T cells by secreting inhibitory 
cytokines TGF-β1 and IL-10, but also by delivering an inhibitory signal via direct 
cell-cell contact. In direct cell-cell contact, cell surface molecules such as CTLA-4 
and ICOS mediate the down-regulatory signal to the eff ector T cells. 
Recent studies have suggested FOXP3 to down-regulate TCR-mediated T-cell 
activation leading to the hyporesponsiveness of activated T cells [284, 285]. Th is 
mechanism negatively down-regulates T-cell responses aft er Ag-specifi c activa-
tion, limiting collateral tissue damage. TCR engagement leads to up-regulation of 
the NFATc2 transcription factor [286]. Together with general transcription factors, 
NFATc2 binds to the FOXP3 promoter region and promotes FOXP3 transcription. 
An increase in the concentration of FOXP3-specifi c transcripts eventually leads 
to the activation of negative feedback loop, and thus to the down-regulation of 
NFATc2 and FOXP3 [287, 288]. In patients with T1D, the type 1 cytokine environ-
ment seems to inhibit the up-regulation of NFATc2. Th is provides a possible expla-
nation for the decreased FOXP3 expression; NFATc2 levels in T1D patients do not 
support the transcription of FOXP3 at similar levels as in healthy children.We also 
found decreased induction of ICOS in T cells stimulated in a type 1 cytokine envi-
ronment in vitro. Diabetic patients already showed decreased ICOS mRNA levels 
in the naïve T -cell population. According to a study by Mesturini et al., ICOS fa-
vors the induction and diff erentiation of Th  eff ector cells when CD3 and CD28 or 
an IL-2 stimulus is present whereas a sub-optimal stimulus would support the dif-
ferentiation of Treg cells [153]. We could not fi nd a diff erence in TGF-β1 or IL-10 
secretion between the study groups. Th is may refl ect the relatively early time point 
of the T-cell culture originally designed for the detection of Th –subtype-specifi c 
transcription factors at the mRNA level. In mice, ICOS-dependent Treg function-
ing in the pancreas during insulitis has been described. In BDC2.5 TCR transgen-
ic mice, the inhibition of ICOS accelerates the disease process and turns insulitis 
into overt diabetes [289]. During the insulitis, both eff ector T cells and Tregs are 
infi ltrated in the infl amed tissue, and the dynamic balance of these two opposing 
Th  subsets dictates the outcome of the pathogenesis process. Th is balance is dis-
turbed if ICOS signaling is lost, and ICOS-mediated IL-10 production is decreased 
in the pancreatic lesions. ICOS-dependent IL-10 regulation has been shown in air-
way hypersensitivity model. Antigen-specifi c Treg induction is also dependent on 
the ICOS-ICOS-ligand interaction [154]. However, contrasting reports on the role 
of ICOS in the pathogenesis of T1D do exist. Hawiger et al. reported in 2008 that 
ICOS is the mediator of the β-cell destruction rather than the mediator of toler-
ance in pancreatic lesions [290]. In a study by Hawiger et al. heterozygous wild 
type mice developed β-cell autoimmunity more aggressively than ICOS defi cient 
littermates. However, the design of this study does not only focus on the role of 
ICOS function in Tregs but on other cell types as well. A dynamic and precise bal-
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ance between co-stimulatory pathways is crucial for the phenotype development 
of the activated T cells, and manipulations leading to a total lack of some factor of 
the scheme may cause an aberrant response. Th us, the role of ICOS in the induc-
tion and maintenance of regulatory mechanisms in human T1D needs to be fur-
ther addressed.
Th e function of FOXP3+ Tregs has been linked to inhibition of the prolifera-
tion of eff ector T cells. CD4+CD25+ cells purifi ed from the type 1 cells generated in 
vitro only showed an inhibitory function in one of the six individuals studied. Iso-
lated cell populations are inevitably heterogeneous, and the proportion of FOXP3+ 
Treg cells in the CD4+CD25+ cell population may not be suffi  cient to produce effi  -
cient inhibition. Another possible explanation for the poor inhibition potential of 
the CD4+CD25+ T cells might be that FOXP3 expression upon stimulation is func-
tionally related to down-modulation of  TCR-mediated activation, instead of pro-
moting an inhibition function in the cells expressing FOXP3. Th us, the expression 
of FOXP3 may be insuffi  cient to induce ‘classic’ regulatory T cells or to identify 
them [284]. 
Th e evidence provided so far on the role of Tregs in T1D is controversial. 
Th e function of Tregs has been reported to be altered in human T1D [277, 291]. 
Lindley and associates have shown defects in patients with newly diagnosed T1D 
as incompetence in inhibiting the proliferation of eff ector T cells upon stimula-
tion. IFN-γ secretion was also higher in co-cultures prepared using CD4+CD25- 
and CD4+CD25+ cells from diabetic patients. In addition, IL-10 secretion was de-
creased in T1D patients in the co-cultures. However, Putnam et al. have reported 
the proportion and function of Tregs to be normal in T1D [278].
Our data show a decreased expression of Treg-related markers in the naïve T 
cell population. A circulating population of naïve Tregs (abbreviated as NnTreg by 
the authors) have been characterized [292]. Th ese cells are nTreg precursors, cells 
that have met their specifi c antigen in the thymus. In contrast to nTregs, natural na-
ive Tregs are able to proliferate in response to autologous APCs, indicating autore-
active T cells to be present in the population of NnTregs. 
Th us, we conclude that poor induction of Treg-associated genes FOXP3, 
NFATc2 and ICOS upon TCR mediated activation of T cells in the type 1 cytokine 
environment may contribute to the pathogenesis of T1D. 
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FIGURE 10. Secretion of IFN- from PBMCs stimulated with CVB4 for 7 days in healthy chil-
dren with no HLA risk genotype, children with T1D, and healthy children with HLA risk gen-
otype. P-value was calculated with Mann-Whitney U-test. Data are shown as box plots (me-
dian, 25% and 75% quartile with whiskers denoting maximal and minimal data points) and 
expressed as pg/ml.
5.3 Impaired Th 1 response against 
 coxsackievirus B4 in T1D 
When PBMCs were stimulated with CVB4, children with T1D showed less IFN-γ 
secretion than healthy children with or without HLA risk genotype (Figure 10) , a 
hallmark cytokine for type 1 cells [293].
In our CVB4 stimulation of PBMCs children with T1D showed impaired up-
regulation of T-bet measured at the mRNA level when compared to healthy chil-
dren with (Figure 11) or without HLA risk genotype (Figure 11). However, when 
the T-bet protein was measured, children without HLA risk genotype showed 
higher T-bet levels (p=0.048) than healthy children, but only a slight tendency was 
observed between healthy children with HLA risk and diabetic children.
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FIGURE 11.  mRNA expression of T-bet in PBMCs stimulated with CVB4 for 7 days from healthy 
children without HLA risk genotype, children with T1D, and healthy children with HLA risk 
genotype. Data are shown as box plots (median, 25% and 75% quartile with whiskers denot-
ing maximal and minimal data points) and expressed as arbitrary relative units.
CXCR6 showed lower expression in CD4+ and CD8+ T cells in children with T1D 
than in healthy children with (p=0.043 and p=0.024) or without HLA-risk geno-
type (p=0.022 and p=0.014). In addition, a lower proportion of CD8+ T cells ex-
pressing IL-12R was observed in patients with T1D in comparison to healthy chil-
dren without HLA risk (p=0.026 ). 
Our data imply that patients with T1D have an impaired response against 
CVB4 in vitro. Diabetic children showed impaired up-regulation of factors close-
ly related to the induction and maintenance of cytotoxic responses, when their PB-
MCs were cultured with CVB4. Th is may cause a slow or incomplete eradication 
of CVB4, and the virus may spread throughout the body. Th us, children with T1D 
may be more susceptible to CVB4 infections, and they may have coxsackieviruses 
infecting pancreatic β cells more oft en than healthy children. Th e type 1 response 
is elementary in the eradication of viruses from the human body. Moreover, effi  -
cient virus clearance from infected tissue demands interaction with chemokines 
and chemokine receptors of Th 1 and cytotoxic type 1 CD8+ cells (Tc1), allowing 
these cells to migrate to the site of infl ammation. Th e induction of IFN-γ expres-
sion is regulated by the transcription factor T-bet. Up-regulation of IL-12Rβ2 by 
T-bet further strengthens the development of the type 1 phenotype of activated T 
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cells, rapidly leading to the establishment of fully committed type 1 T cells. IFN-γ 
production is synergistically induced by the engagement of IL-12 receptors. Low 
expression of T-bet may be responsible for the reduced percentage of T cells ex-
pressing the IL-12Rβ2 chain. Our fi nding of lowered T-bet expression in the PB-
MCs of T1D patients, but not in healthy control children, refers to impaired virus 
responses in T1D patients. CVB4 induces the expression of IFN-γ, IL-1β, TNF-α, 
IL-2, and IL-10 in healthy donor PBMCs [294]. Proper interferon signaling has 
been shown to be crucial for β-cell protection in CVB4 infection [295].
General impairment in the generation of the type 1 response generation in vit-
ro has been observed in T1D in some studies. Reduced levels of intracellular IFN-γ 
in CD4+ T cells was reported in a study by Kukreja et al., when PBMCs of both re-
cent-onset and long-lasting T1D patients were stimulated with PMA and ionomy-
cin [271]. In another study, decreased IFN-γ and IL-10 secretion of PHA-stimu-
lated PBMCs was observed in children and young adults with T1D in comparison 
to healthy control subjects [296]. Fresh PBMCs of children with newly diagnosed 
T1D showed decreased secretion of IFN-γ and TNF-α in a study by Lohmann et 
al. [297]. In addition, anti-CD3 and antiCD28 stimulation of eff ector T cells result-
ed in a decreased production of IFN-γ in T1D patients when compared to healthy 
controls [291]. HLA loci determine approximately 50% of the genetic risk of T1D. 
HLA molecules play a central role in the presentation of antigens to CD4+ and 
CD8+ T cells. It has been shown that HLA molecules modify the outcome of T-cell 
responses against diff erent pathogens and antigen structures. Th e HLA haplotype 
is known to modify immune responses against CVB4. Children positive for HLA-
DR3 showed a decreased frequency of T lymphocytes responding to CVB4, where-
as HLA-DR4-positive children showed an increased frequency of T cells respond-
ing to CVB4 [298]. Sadeharju et al. have shown that children with the T1D risk 
haplotype HLA-DR3 and/or HLA-DR4 have a higher antibody response towards 
CVB4 than healthy children with the protective HLA-DR2 haplotype [299]. Th is 
may mirror the decreased type 1 responses in T1D patients, and thus the increased 
activity of Th 2 cells providing help for B cells. However, in our study, no diff erenc-
es were seen between healthy children with or without the HLA risk genotype re-
garding the expression levels of markers associated with type 1 responses. Howev-
er, a diff erence was seen between HLA-DR4-DQ8 matched diabetic patients and 
healthy control children. In accordance with the results of our study, Juhela et al. 
have shown a decreased proliferation of T cells against purifi ed CVB4 in children 
with T1D compared with healthy control children [300]. 
We conclude that children with T1D appear to have an impaired immune re-
sponse against CVB4. A poor type-1 response seems not to be associated with HLA 
risk genotypes at least in vitro. Children with T1D may be more susceptible to sub-
tle and prolonged CVB4 infections, and thus an increased frequency and propor-
tion of β-cell death. Th is may cause the priming of autoreactive T cells, and thus 
β-cell autoimmunity in the pancreatic lymph nodes via antigen presentation by the 
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APCs. Whether the impaired type 1 responses are restricted to CVB4, or wheth-
er it is an impairment of antigen-specifi c activation in general needs to be further 
evaluated.
Enteroviruses, and particularly coxsackieviruses, are considered as one possi-
ble environmental trigger in the pathogenesis of T1D. Enteroviruses were associat-
ed with T1D for the fi rst time in 1969, when patients with recent-onset T1D were 
shown to have higher antibody titers against the coxsackievirus B4 strain than un-
aff ected control subjects [240]. Additionally, enterovirus infections have been asso-
ciated with the appearance of β-cell autoimmunity [301, 302]. Several studies have 
shown children with T1D and prediabetic children to more oft en have coxsackie-
virus RNA or antibodies against coxsackieviruses in their blood circulation [239, 
240, 242, 244-248]. Th us, children with T1D or at genetic risk of T1D may be more 
prone to coxsackievirus infections. Th e role of coxsackieviruses in the course of 
T1D is further supported by reports that show CVB4 being able to infect human  β 
cells both in vitro [249] and in vivo [250], which may in turn induce the β-cell au-
toimmunity or support it.
5.4 Increased Th 17 activation in human T1D 
When PBMCs from T1D patients and healthy children were stimulated with anti-
CD3 and anti-CD28, enhanced IL-17 secretion (Figure 12, panel A) in children 
with T1D was observed. IL-17 secretion correlated strongly with the measured 
mRNA levels of IL-17 in T1D patients.
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FIGURE 12.  Overwhelming IL-17 secretion upon T-cell activation in human T1D. IL-17 levels in 
culture supernatant samples (panel A). IL-17 protein levels and IL-17 mRNA levels correlat-
ed strongly in stimulated PBMCs from T1D patients (panel B) (Spearman R=0.72, p=0.0026). 
For pairwise comparisons, p -values were calculated with the Mann-Whitney U-test. The cor-
relation co-effi cient of IL-17 protein levels and IL-17 mRNA levels was calculated using the 
Spearmank rank correlation test. On the panel A data are shown as box plots (median, 25% 
and 75% quartile with whiskers denoting maximal and minimal data points) and expressed 
as pg/ml.
Transcription factor RORC2 also showed higher mRNA expression in stimulated 
PBMCs of T1D patients than healthy control children (Figure 13, panel A). Simi-
larly, Treg-associated transcription factor FOXP3 was expressed at higher levels in 
response to T-cell activation in children with T1D than in healthy children (Figure 
13, panel B). Th e levels of RORC2 and IL-17 transcripts induced upon T-cell ac-
tivation correlated with secreted IL-17 in children with T1D (rho=0.599, p=0.018 
and rho=0.717, p=0.003). Th 17-associated cytokine IL-22 was expressed at high-
er levels in stimulated PBMCs of T1D patients in comparison to healthy children. 
Th e induction of IL-22 has been reported to be Ahr-dependent. However, we did 
not fi nd a diff erence between the study groups in the expression of Ahr in stimu-
lated PBMCs (data not shown).
70
5  Results and discussion
Studies of Immune Regulation 
in Type 1 Diabetes
THL –  Research 45/2010
A B 
FIGURE 13. Upon stimulation, PBMCs of diabetic children showed increased up-regulation of 
Th17 signature transcription factor RORC2 (panel A) and Treg signature transcription factor 
FOXP3 (panel B). p -values were calculated with the Mann-Whitney U-test. Data are shown as 
box plots (median, 25% and 75% quartile with whiskers denoting maximal and minimal da-
ta points) and expressed as arbitrary relative units.
IFN-γ and T-bet mRNA up-regulation in diabetic and healthy children did not dif-
fer between the study groups. Th e existence of IL-17 and IFN-γ co-producing T 
cells has been reported in autoimmune diseases [303], and we thus examined the 
relation between the IL-17 and IFN- response in T1D. We found that in children 
with T1D, the IFN-γ response, both at the mRNA and protein level, correlated with 
IL-17A secretion of the anti-CD3 and anti-CD28 stimulated PBMCs (rho=0.652, 
p=0.006 and rho=0.735, p=0.002).
Anti-CD3 and anti-CD28 stimulation of T cells caused an overwhelming Th 17 
response in children with T1D, but not in healthy children. To determine wheth-
er increased Th 17 activity could be seen in vivo in patients with T1D, we examined 
the mRNA levels of Th 17-related genes from the circulating memory CD4+ cells of 
nine children with T1D and eight healthy children. IL-17A and IL-22 mRNA were 
expressed at higher levels in the population of freshly purifi ed peripheral blood 
CD45RO+CD4+ memory cells from children with T1D. Minimal or undetectable 
expression levels were seen in healthy children (6/8 vs 0/8, p=0.007 for IL-17 and 
5/8 vs 0/7,  p=0.026 for IL-22).
IFN- mRNA expression in CD45RO+CD4+ cells showed no diff erence be-
tween T1D patients and healthy children. Higher mRNA levels of FOXP3 were ob-
served in the CD45RO+CD4+ cell compartment of T1D patients when compared to 
healthy children (5/8 vs. 0/8, p=0.026). 
According to fl ow cytometry analysis, PBMC stimulation with anti-CD3 and 
anti-CD28 increased the percentage of CD4+ T cells positive for IL-17, whereas 
CD4- T cells positive for IL-17 were rarely observed (Figure 14). 
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FIGURE 14. Phenotype characterization of Th17 cells generated upon T-cell stimulation. An in-
crease in IL-17-positive cells was observed most often among CD4+ cells, whereas CD4- T cells 
did not show IL-17 production.
 
 
 
 
 
 
 
 
 
0.6% 
Over 90% of the CD4+ T cells expressing IL-17 upon stimulation were also ex-
pressing CCR6 (Figure 15, panel B, median 95.2%, range 81-99.4%: n=7 diabetic 
children). IL-17-positive CD4+ T cells were TCRαβ+ (Figure 15, panel D).
When anti-CD3 and anti-CD28 stimulated PBMCs of T1D patients were stud-
ied by fl ow cytometry regarding the expression of IL-17 and IFN- double-positive 
cells were observed in 4 children out of 11 (Figure 16, panel B). We did not screen 
systematically healthy children for IL-17 and IFN-γ double-positive cells.
Th 17 immunity has been associated with the development of autoimmune di-
abetes in animal models. In NOD mice elevated IL-17 transcript levels were found 
to correlate with the progression of insulitis to diabetes both in the pancreas and 
blood circulation [273]. It has also been shown that in NOD mice the inhibition 
of Th 17 cells controls autoimmune diabetes, but the role of IL-17 immunity seems 
to be associated rather with the progression of the diabetic disease process during 
β-cell destruction than with the initiation of β-cell autoimmunity [275, 304]. Con-
vincing evidence for the role of Th 17 cells in the pathogenesis exists from animal 
models of T1D. However, direct evidence for the role of Th 17 cells in human T1D 
is so far scarce. Anti-CD3 and anti-CD28 stimulation of PBMCs from T1D pa-
tients signifi cantly up-regulated IL-17 at both the mRNA and protein level in as-
sociation with Th 17-specifi c transcription factor RORC2 and Th 17-associated cy-
tokine IL-22 when compared to healthy children. A similar diff erence was also seen 
at the mRNA level in CD4+CD45RO+ memory cells of T1D patients in comparison 
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FIGURE 15. Phenotype analysis of IL-17-positive cells in T1D. Gating strategy for CCR6- and 
CCR6+ CD4 cells (panel A). A representative dot plot of IL-17-expressing cells among CD4+ 
CCR6+ cells (panel B) and CD4+CCR6- cells (panel C) from anti-CD3 plus anti-CD28 stimulated 
peripheral blood mononuclear cells from a child with newly diagnosed T1D. (panel D) A rep-
resentative dot plot of anti-CD3 plus anti-CD28 stimulated peripheral blood mononuclear 
cells from a child with newly diagnosed T1D showing that CD4+ T cells expressing IL-17 are 
TCRαβ positive. 
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to those of healthy children, suggesting that the activation of IL-17/IL-22 pathways 
is a major alteration in T1D. 
Th 17 immunity is considered as an important function of the mucosal barri-
er, and the activation of Th 17 cells provides protection against bacterial and fun-
gal infections [204]. In this function, the IL-22 cytokine has a central role. IL-22 is 
preferentially expressed by the Th 17 cells, both in the early stages of polarization of 
naïve CD4+ T cells towards the Th 17 phenotype, and when Th 17 cells are restim-
ulated. IL-22 acts directly on epithelial cells, and some fi broblast cells in peripher-
al tissue also respond to IL-22 and it induces an acute phase response both in vit-
ro and in vivo [305-310]. Th us, IL-22 seems to coordinate innate immunity, but it 
also contributes to the modulation of tissue organization, and this may be an im-
portant function of IL-22 in respect to autoimmune diseases. IL-22 in conjunction 
with IL-17 synergistically induces the expression of antimicrobial peptides [311]. 
Th e IL-22 receptor is not expressed on immune cells, and thus the IL-22 cytokine is 
used for communication between immune cells and tissues. Th ere is no direct evi-
dence for the role of IL-22 in human T1D. However, a recent report has shown that 
IL-22R1 is expressed in pancreatic β cells. Th us, T-cell-mediated immunity may 
modulate the function of human pancreatic islets via IL-22 signaling [312]. We ob-
served higher expression of IL-22 in stimulated PBMCs of T1D patients. In animal 
models, the induction of IL-22 has been reported to be Ahr-dependent [199, 200]. 
When we measured Ahr levels from the stimulated PBMCs, we could see no diff er-
ence in the mRNA levels of Ahr between T1D patients and healthy children (Fig-
ure 14, panel B). Th us, the diff erence we observed in the IL-22 expression levels 
may not be explained by abnormalities in signaling pathways associated with the 
Ahr expression. However, functional abnormalities in transcriptional complex reg-
ulating IL-22 gene expression, which Ahr is a part of, may still be involved in the 
pathogenesis of T1D, and need to be evaluated in future studies.
Interestingly, in addition to higher expression of IL-17, RORC2, and IL-22 we 
also observed increased expression of FOXP3 transcripts in both activated T cells 
and memory CD4+ cells, while IFN-γ and transcription factor T-bet showed sim-
ilar expression both in stimulated PBMCs and memory T cell compartment levels 
when T1D patients were compared to healthy children. Th is suggests simultaneous 
up-regulation of regulatory mechanisms and the IL-17 pathway in T1D. Tregs may 
lose their ability to express FOXP3, and begin to secrete infl ammatory cytokines 
IFN-γ or IL-17, blurring the picture of the Treg/Th 17 scheme even more. FOXP3 is 
a key molecule in maintaining the regulatory functions of CD4+ T cells. If FOXP3 
expression is lost, eff ector functions may be promoted in the so-called ex-regula-
tory T cells. Th ese exFOXP3 cells, which formed a signifi cantly higher percentage 
in the autoimmune diabetes setting, were able to transfer diabetes [7]. Accumulat-
ing evidence shows that human Tregs may diff erentiate into IL-17-producing cells 
[313-315]. Some studies suggest that pathogenic T cells in autoimmune conditions 
are co-producers of IL-17 and IFN- or that a shift  from Th 17 to Th 1 cells makes 
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IL-17 cells pathogenic [6, 303]. Highly purifi ed Th 17 cells with specifi city for an is-
let cell antigen were diabetogenic when converted into IFN- secreting Th 1-like 
cells [5]. Because co-producers of IL-17 and IFN- have been observed in autoim-
mune diseases, we examined the relation between the IL-17 and IFN-γ response 
in T1D. When PBMCs from diabetic patients were stimulated, simultaneous pro-
tein expression of IFN-γ and IL-17 was seen in a small proportion of CD4+ T cells. 
It seems that in T1D some CD4+IL-17+cells are also IFN-γ co-producers. Th e pro-
duction of IL-17 and IFN-γ by the same T-cell population in children with T1D 
further suggests that at least some of the  IL-17-secreting T-cells associated with 
T1D are not functionally committed T-cells.
TGF-β1 has been thought to be primarily an anti-infl ammatory cytokine. 
TGF-β1 induces the expression of FOXP3 in vitro, and thus diff erentiates activated 
naïve T cells to Tregs. Recent progress in the fi eld of T-cell biology has brought con-
troversial knowledge on the role of TGF-β1. On the other hand, TGF-β1 has broad 
inhibitory eff ects on the immune system, but it is absolutely required for the induc-
tion of a pro-infl ammatory response to eradicate certain bacteria and fungi. Th e re-
ciprocal relationship between Tregs and Th 17 cells was fi rst demonstrated by Bet-
telli et al. [185], and further elucidated by Littman and colleagues [191]. Although 
TGF-β1 induces FOXP3 expression in naïve T cells, IL-21 inhibits this regulation 
and together with TGF-β1 drive the development of Th 17 cells. In synergy with 
TGF-β1, IL-1β, and IL-6 drives the re-call of memory Th 17 cells [193]. Th e role of 
Th 17 immunity in human T1D was indirectly supported by the observation that 
monocytes from patients with T1D showed spontaneous activation of IL-6 and IL-
1, and the monocytes isolated from diabetic patients were able to induce IL-17 de-
viation  in allogenic memory T-cells in vitro [276]. However, we could fi nd no dif-
ferences in IL-6 levels when the  plasma of T1D patients and healthy children was 
analyzed. To further characterize the possible role of IL-6 and IL-1β in T1D, we an-
alyzed the mRNA levels of IL-6 and IL-1β of the eight T1D patients and eight non-
related auto-antibody negative siblings of T1D patients. We did not confi rm the 
up-regulation of IL-6 and IL-1β in T1D patients. Contradictory results regarding 
the IL-6 levels may be explained by the age composition of the study groups, since 
our study only included children under the age of 15, whereas the study by Brad-
shaw et. al. also included adult subjects [276].
Th e IL-17 producing CD4+ T cells in children with T1D expressed CCR6, an 
established chemokine receptor for Th 17 cells [316, 317]. Peripheral blood and 
lymphoid tissue-derived CCR6-expressing Tregs have been shown to produce IL-
17 upon activation [318]. CCR6 is typically expressed on T lymphocytes show-
ing homing properties to mucosal surfaces [316, 317]. Th 17 immunity is consid-
ered as an important function of the mucosal barrier, and the activation of Th 17 
cells provides protection against bacterial and fungal infections [204]. Overwhelm-
ing activation of Th 17 immunity has been associated with autoimmune conditions 
and infl ammatory bowel disease [319]. Both human and animal models of T1D 
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have shown that lymphocytes infi ltrating into the pancreas express mucosal hom-
ing properties [320-322]. Aberrancies of the gut immune system, such as subclin-
ical intestinal infl ammation [267, 323] and increased gut permeability [324, 325], 
have also been associated with human T1D. At least TCRγ/δ-expressing T cells 
have been shown to be IL-17 producers in mice [326, 327]. However, in children 
with T1D, IL-17-expressing CD4+ T cells were positive for TCRα/ Nevertheless, 
aberrant mucosal immunity may be involved in the course of T1D. Factors contrib-
uting to the regulation of the mucosal barrier in the gut are probably the next in-
teresting fi eld in T1D research. For example, the eff ect of environmental toxins on 
the function of the mucosal immune system may play a part in T1D pathogenesis. 
It has already been shown that the Treg/Th 17 balance can be modulated by diox-
in via a mechanism mediated by Ahr [199, 200], providing a link between environ-
mental pollutants and altered immune regulation [200]. 
Tregs expressing CCR6 can produce IL-17 upon activation and simultaneous-
ly express both FOXP3 and RORC2 [318]. Interestingly Tregs induced to express 
IL-17 are still potent inhibitors of the proliferation of CD4+ eff ectors. It has been 
demonstrated that CCR6-negative FOXP3-expressing cells can diff erentiate into 
IL-17-producing cells when stimulated and treated with exogenous IL-2 and IL-
15. Th e diff erentiation could be further enhanced if additional IL-1β, IL-23 or IL-
21 were also present [315]. 
We observed overwhelming upregulation of Th 17 immunity in T1D patients 
upon T cell stimulation. According to fl ow cytometry analysis, IL-17 was produced 
in CD4+ T cells, and not by CD8+ cells, or other cell types. Our data on isolated 
memory CD4+ cells support the view that memory T cells, and not naive diff eren-
tiating cells were the origin of upregulated Th 17 immunity. We used ‘classical’ an-
ti-CD3+ antiCD28 stimulation for the activation of PBMC. Th e relatively short in-
cubation time of 40h may not be long enough to result in diff erentiation of IL-17 
secreting cells with CCR6+ expression. Simultaneous up-regulation of FOXP3 and 
Th 17-related genes suggests that dysregulation of the balance of Tregs and Th 17 
cells may play a role in T1D pathogenesis. Alternatively, FOXP3 upregulation may 
be feedback activation of regulatory mechanisms as response to overwhelming 
Th 17 immunity in patients with T1D. In conclusion, our results indicate that dys-
regulated Th 17 activation may be involved in T1D pathogenesis.
5.5 IL-17 eff ects on pancreatic islets
Up-regulation of IL-17 related genes upon T-cell stimulation in T1D patients raised 
the question of the eff ects of IL-17 on pancreatic β cells. Th e eff ects of IL-17 on hu-
man β cells in vitro were studied as such or in combination with other infl ammato-
ry mediators, namely IL-1β and IFN-γ. Both IL-17 receptor variant A and C mR-
NA transcripts were detected in human islet RNA preparations by RT-qPCR.
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A 
B 
FIGURE 17. IL-17 contributes to the activation of the infl ammatory and pro-apoptotic respons-
es in human islets. IL-17 inhibits the expression of BCL-2 and up-regulates the expression of 
SOD2 in human islets treated with IL-17 (panel A, black bars) in comparison to negative treat-
ment (panel A, white bars). In combination with IL-1 and IFN-γ (panel B, white bars), IL-17 
enhances the expression of nitric oxide synthase (NOS2A) and cyclo-oxygenase (COX-2) (pan-
el B, black bars). Bars represent mean, and whiskers standard deviation. Student’s t-test for 
paired samples was used for calculation of p-values.
IL-17 treatment up-regulated the transcription of superoxide dismutase 
(SOD2), and down-regulated the transcription of anti-apoptotic gene BCL-2 (Fig-
ure 17, panel A) in human islets. In synergy with IL-1β and IFN- γ, IL-17 enhanced 
the transcription of the inducible isoform of nitric oxide synthase (iNOS), and cy-
clo-oxygenase (COX-2) in human islets (Figure 17, panel B). 
We also analyzed the potential apoptotic eff ect of IL-17, and observed an en-
hanced apoptotic eff ect of IL-17 with IL-1β and IFN-γ on human islet cell prep-
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arations, and on the MIN6 cell line. Images were produced showing the necrotic 
plus apoptotic cells identifi ed by the white nuclear staining and fragmented nuclei 
(arrows indicating positive cells) in a human islet cell preparation (Figure 18, left  
panel) and in MIN6 cells (Figure 18, right panel) when treated with IL-17 together 
with IL-1β and IFN-γ (Figure 18, lower images) and an untreated control (Figure 
18, upper images). Th e p -values were calculated with the paired t-test.
IFN-γ secretion by Th 17 cells may result in additive β-cell damage due to the 
synergistic eff ects mediated by IFN-γ and IL-17 on human islet cells as we dem-
onstrated here. IL-17R is expressed on human islets and IL-17 potentiated the in-
fl ammatory and apoptotic response in human islet cells in vitro. Th e up-regulation 
of iNOS and SOD results in the increased production of free-radicals that inter-
fere with β-cell functioning and cause β-cell damage. IL-17 triggers iNOS activa-
tion in endothelial cells, and endothelial cells participate in the regulation of the 
T-cell-dependent infl ammatory response [328]. IL-17 has been demonstrated to 
augment iNOS expression and subsequent NO production by diff erent combina-
tions of IFN-γ, TNF-α, and IL-1β. In addition, a signifi cant increase in blood IL-17 
levels was observed in a multiple low-dose streptozotocin model of diabetes, sug-
FIGURE 18. Examples of necrotic plus apoptotic cells identifi ed by white nuclear staining and 
fragmented nuclei (arrows indicating positive cells) in human islet cell preparation (left pan-
el) and in MIN6 cells (right panel) when treated with IL-17 together with IL-1 and IFN-γ (low-
er images) and untreated control (upper images). Pictures were originally taken at 20x mag-
nifi cation.
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gesting that T-cell-derived IL-17 might be involved in the NO-dependent damage 
of  cells in T1D [274].
Down-regulation of the anti-apoptotic gene BCL-2 was seen, as well as in-
creased apoptosis of islet cells when treated either with IL-17 alone or together 
with other infl ammatory cytokines, such as IL-1 and IFN-γ[329]. Th us, the syn-
ergistic eff ect of IFN-γ and IL-17 in the induction of infl ammation and apoptosis 
in the human islet cells indeed suggests that the co-producers of IL-17 and IFN-γ 
could be of clinical importance. Furthermore, the results could indicate that anti-
gen-specifi c T-cell-mediated attack is not necessarily needed for β-cell destruction, 
which could be mediated by other factors such as cytokines including IL-17. Th e 
detrimental eff ect of IL-17 on human islet cells emphasizes the role of IL-17 in the 
pathogenesis of β-cell destruction without the prerequisite of an autoantigen-spe-
cifi c attack against insulin-producing β cells. However, autoantigen-specifi c T cells 
producing IL-17 may exist. Indeed, GAD specifi c T-cell clone has been reported to 
produce IL-17, thus providing link to the pathogenesis of T1D. 
Our results here suggest that IL-17 is detrimental to human β cells. Th 17 acti-
vation may increase apoptosis of β cells, and thus the release of β-cell-derived auto-
antigens, which would accelerate the development of β-cell specifi c autoimmunity.
5.6 Screening method for FOXP3 gene 
 expression modulators in human Tregs
From the PBMC fraction, CD4+CD25+ target cells were purifi ed with a MACS sep-
aration technique, and the purity of the CD4+CD25+ cell population was constant-
ly greater than 90%. Magnetic particle technology was used for mRNA purifi cation 
from the isolated target cells. Using purifi ed mRNA as a template, cDNA was pre-
pared and TaqMan technology was used for the analysis of beta-2-microglobulin 
(B2M) and FOXP3 expression levels. Th e eff ect of the anti-CD3 coating on B2M 
and FOXP3 expression levels was analyzed. Anti-CD3 coating of the cell cultur-
ing wells improved the signal levels and reduced the observed variation for both 
B2M and FOXP3. Mean Ct values for B2M were 25.2 (SD=0.37) and 25.9 (SD=1.1) 
for eight cell culturing wells with and without anti-CD3 coating, respectively. Th e 
mean Ct values for FOXP3 were 28.8 (SD=0.28) and 31.1 (SD=0.51) , respective-
ly, for eight cell culturing wells with and without anti-CD3 coating. When diff erent 
numbers of CD4+CD25+ cells were used for analysis, we observed that Ct values of 
B2M and FOXP3 were dependent on the cell numbers used for analysis when lin-
ear regression analyses were performed (R2=0.77, p<0.001 for B2M and R2=0.72, 
p<0.001 for FOXP3), whereas dCt values were independent of the cell numbers 
used for analysis (R2=0.02, p=0.55) (Figure 19).
79
5  Results and discussion
Studies of Immune Regulation 
in Type 1 Diabetes
THL –  Research 45/2010
0 5000 10000 15000 20000 25000
0
10
20
30
40
Cell Number
C
t -
va
lu
e
FIGURE 19. Linear regression of Ct values for B2M , FOXP3 and dCt determined from various 
quantities of unstimulated CD4+CD25+cells (quadruplicates). The dCt –value of the gene ex-
pression analysis is not dependent on the cell number used in the analysis in the range from 
1250 to 20 000 cells. B2M, R2=0.77, p<0.001, FOXP3, R2=0.72, p<0.001, dCt, R2=0.02, p=0.55. 
Ct(B2M)=, Ct(FOXP3)=, dCt=. Mean±SD is shown in the fi gure.
When relative FOXP3 expression analysis was performed from the untreated 
CD4+CD25+ cells, and from the CD4+CD25+ cells stimulated with either the anti-
CD3 alone or in combination with anti-CD28 and cytokine TGF-β1, we observed 
the relative FOXP3 expression levels presented  in Figure 20. Spearman’s rank cor-
relation coeffi  cient was calculated for the dCt and Ct values for both  the FOXP3 
and reference gene B2M for diff erent cell populations and treatments. Ct values for 
FOXP3 expression correlated with the dCt values (r=0.94, p<0.0001). No correla-
tion (r=-0.02, p=0.93) was seen between Ct values for the reference gene B2M and 
dCt values.
Functional defects in Tregs have been associated with autoimmune diseases 
[330]. Th e proportion of Tregs in peripheral blood circulation is limited, and the 
detection  method for gene expression should thus be sensitive and robust with 
a broad dynamic range. RT-qPCR matches these requirements [331, 332]. Quan-
titative reverse transcription PCR (RT-qPCR) in combination with a magnetic-
particle-based mRNA capture technique was used for the quantitation of FOXP3 
gene expression in CD4+CD25+ human Tregs. We detected FOXP3 expression even 
from  ~1200 CD4+CD25+ cells, and changes in the Ct values of the reference gene 
B2M and FOXP3 were linear from ~1200 cells to 20 000 cells. However, the dCt 
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FIGURE 20. Comparison of relative expression levels of FOXP3 mRNA in CD4+CD25+ cells (con-
trol) and in CD4+CD25+ cells stimulated with anti-CD3 or with anti-CD3 and anti-CD28 and 
FOXP3 promoting cytokine TGF-1. The horizontal line shows the average FOXP3 expression 
of the anti-CD3-stimulated CD4+CD25+ cells..
value remained constant across the range of cell quantities. Th us, we decided to 
use approximately 5000 CD4+CD25+ cells in the FOXP3 gene expression analy-
ses in later studies. When CD4+CD25- and CD4+CD25+ cells and diff erent biolog-
ical treatments given to these cells were analyzed, we observed that CD4+CD25+ 
cells almost exclusively showed spontaneous FOXP3 expression. Th is is in con-
cordance with an earlier report (271), which also showed that CD4+CD25- cells 
up-regulate FOXP3 upon stimulation to some extent. Spontaneous FOXP3 expres-
sion was, however, markedly higher in CD4+CD25+ cells, and FOXP3 expression 
above the cut-off  criteria (mean+3*SD) can be considered to have originated from 
CD4+CD25+ cells. Our methodology successfully distinguished diff erent biologi-
cal treatments given to the CD4+CD25+ and CD24+CD25- cells. When the relation-
ship between the B2M and FOXP3 dCt values was examined in CD4+CD25+ and 
CD4+CD25- cells with or without stimulation, a strong correlation was observed 
between the Ct values of FOXP3 and dCt values. Th us, we concluded that the nor-
malized relative expression estimate of FOXP3 is dependent on the changes in the 
Ct values of FOXP3. Th is validates the use B2M for mRNA input normalization.
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5.7 Results of the pilot screen
In the pilot screen for the FOXP3 up-regulation potential of 160 small molecules, 
the mean expression level plus 3*SD units of the anti-CD3 treated cells was consid-
ered as a cut-off  for the up-regulation of FOXP3 expression. For the fi rst screened 
plate (80 molecules), the mean + 3*SD FOXP3 expression for the anti-CD3-stimu-
lated CD4+CD25+ cells was 2.3 relative units (mean = 1.05, SD = 0.41), and for the 
second plate (80 molecules) 1.5 (mean = 1.01, SD = 0.12). Using this cut-off  crite-
rion, from the 160 diff erent chemicals screened, six fulfi lled the criterion and were 
considered as potential FOXP3 up-regulators (See Figure 21, Panels A and B, for 
Plates 1 and 2 respectively). 
Four chemicals with FOXP3 up-regulation potential were purchased and re-
analyzed using CD4+CD25+ cells from six diff erent donors. Table 2 shows the ob-
served inter-individual variation in the FOXP3 up-regulation induced by the four 
diff erent molecules.
FIGURE 21. mRNA expression levels of the FOXP3 in CD4+CD25+ cells induced by 160 drugs or 
drug-like molecules included in the pilot screen. Observations within a plate are arranged in 
order according to the FOXP3 expression levels. Red triangles represent the FOXP3 expres-
sion levels of cell culturing wells with bare anti-CD3-stimulated CD4+CD25+ cells.
Table 2. Table 2. FOXP3 expression in chemically treated (1.0µM) CD4+CD25+ cells from six dif-
ferent donors. The expression of FOXP3 induced by chemical treatment is relative to the ex-
pression of FOXP3 in anti-CD3 stimulated CD4+CD25+ cells.
Tested 
individual
Inter-individual variation of FOXP3 expression in chemical stimulated Tregs
Phenylbutazone Resveratrol Fluphenazine 
hydrochloride
Oxyphencyclimine
A 1.34 0.65 0.94 0.65
B 0.67 0.53 1.33 0.91
C 1.61 0.62 0.46 0.56
D 1.62 2.61 1.58 1.54
E 1.75 1.21 1.36 0.31
F 1.38 1.03 1.10 0.99
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FIGURE 22. PB up-regulated FOXP3 in a concentration-dependent manner in anti-CD3-stimulat-
ed CD4+CD25+ cells. Three phenylbutazone concentrations (0.1µM, 1.0µM, and 10µM) were 
tested on CD4+CD25+ cells from two donors. R2 = 0.87, p = 0.007.
Phenylbutazone (PB) showed a FOXP3 up-regulation potential in fi ve out of six 
tested individuals. PB-induced up-regulation of FOXP3 was signifi cant (p = 0.03, 
Wilcoxon Signed Rank Test). In addition, the dose response of FOXP3 up-regula-
tion induced by PB was examined. Th e average FOXP3 expression for anti-CD3-
stimulated and 0.1μM, 1.0μM, and 10μM phenylbutazone treated CD4+CD25+ cells 
was 1.3 RU (SD = 0.18), 1.6 (SD = 0.007) and 2.7 RU (SD = 0.29), respectively (Fig-
ure 22). 
Th e biological relevance of the transcription factor FOXP3 is rather well doc-
umented. However, the pathways regulating the expression of FOXP3 are still un-
clear. Th e functioning of Tregs has been shown to mainly be initiated by FOXP3-
dependent mechanisms [286], and FOXP3 dysfunction has been characterized in 
many autoimmune diseases [330]. It has been demonstrated that marginal FOXP3 
up-regulation in purifi ed CD4+CD25+ Tregs leads to a signifi cant increase in the 
suppressive capacity of Tregs [286]. 
Th e chemical genomics strategy is a system biology research approach used 
successfully in industrial drug discovery. Chemical genomics applies a cell-based 
screening methodology, leaving a high degree of freedom for the model system to 
iterate a new balance in response to the applied chemical. Th us, we aimed to devel-
op a method for the screening of small molecule entitites (small molecule < 1000 
Daltons) up-regulating FOXP3, using primary human CD4+CD25+ cells as our tar-
get cell model. Th e screening strategy to characterize molecules with a FOXP3 up-
regulating potential is presented in Figure 23. 
Aft er the automation and optimization of the FOXP3 quantifi cation using 
limited primary cell resource of CD4+CD25+ cells, the methodology was applied on 
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FIGURE 23. Strategy for the screening of small molecules up-regulating FOXP3 transcription in 
human CD4+CD25+ cells derived from peripheral blood. 
a small-scale pilot screening of FOXP3 modulators. Th e method to monitor the up-
regulation of FOXP3 in anti-CD3 stimulated and chemical-treated cells was proven 
to be feasible, and we found modulators of FOXP3 gene expression. Th e sensitiv-
ity of the screening method enables the use of small cell numbers in the screen-
ing, and the methodology is thus particularly suitable for screening approaches 
targeting human blood-derived primary cells. As anti-CD3 stimulation increased 
FOXP3 gene expression in CD4+CD25+ cells, the screening method could be used 
in the search for FOXP3 down-regulators.
In the pilot screen, PB showed a FOXP3 up-regulation potential in fi ve out of 
the six individuals studied. In addition, PB up-regulated FOXP3 in a dose depend-
ent manner with three tested concentrations and the dose dependency of FOXP3 
up-regulation by PB was seen in CD4+CD25+ cells from two diff erent donors. PB is 
a strong anti-infl ammatory agent, that has been shown to inhibit pro-infl ammatory 
cytokines IL-6 and GM-CSF of anti-CD3 and anti-CD28 stimulated PBMCs [333], 
and IL-6 production by adherent cells stimulated with lipopolysaccharide (LPS) 
[334]. Th e molecular mechanism through which PB mediates its anti-infl ammato-
ry action is not known. FOXP3 mediates the repression of cytokine expression, and 
PB may therefore inhibit cytokine expression by up-regulating FOXP3.
In conclusion we have developed a screening method that is feasible for the 
screening of modulators of FOXP3 gene expression in human Tregs. Our method-
ology can easily be applied to other similar approaches where the target cell popu-
lation is limited. Such an approach would be the characterization of FOXP3 expres-
sion in recently discovered Th 17 cells, which have been shown to be closely related 
to the human Tregs. Th e screening of drug molecules that modulate the dynamic 
balance of Tregs and Th 17 cells could provide new insights for drug development 
to cure immune-mediated diseases.
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6 Conclusions
Rapidly accumulating knowledge suggests that defective regulation of T-cell re-
sponses plays an essential role in the pathogenesis of autoimmune diseases such as 
T1D. Th e development of T1D is a long and complex process depending on a fi ne 
balance between pathogenic and tolerogenic immunological pathways. Recent ad-
vances in the fi eld of T-cell biology have revealed new and more dynamic mecha-
nisms in the control of immune reactions. Advances in Treg research, in particular, 
have revolutionized the concept of immune regulation. Tregs can lose their regula-
tory features and turn into self-antigen-recognizing eff ector T cells producing pro-
infl ammatory cytokines such as IFN-γ and IL-17. Th e work presented in this thesis 
aimed at assessing the alterations in the regulation of T-cell responses generated in 
T1D. Th e results suggest that the generation of regulatory mechanisms and eff ector 
mechanisms upon T-cell activation is aberrant in children with T1D. In our stud-
ies, an in vitro cytotoxic environment inhibited the induction of genes associated 
with regulatory functions, namely FOXP3, NFATc2, and ICOS, upon T-cell activa-
tion. We also found T1D patients to have an impaired cytotoxic response against 
coxsackievirus B4. Ineff ective virus clearance may increase the apoptosis of β cells, 
and thus the risk of β-cell specifi c autoimmunity, due to the increased presentation 
of β-cell-derived peptides by APCs to T cells in pancreatic lymph nodes. 
IL-17 immunity has been shown to contribute the pathogenesis of T1D in an-
imal models. We demonstrated IL-17 activation to be a major alteration in T1D 
patients in comparison to healthy children. Moreover, alterations related to the 
FOXP3-mediated regulatory mechanisms and to the generation of a Th 1 response 
was associated with the IL-17 up-regulation seen in T1D patients. 
T1D is believed to result from an imbalance between auto-reactive eff ector T 
cells and Tregs. Th is concept is built on the assumption that T-cell subsets are stat-
ic entities. In the light of current knowledge, this view seems oversimplifi ed. Th e 
plasticity of activated T cells as well as Tregs seems to be a critical mechanism for 
the human body to ‘edit’ immunological functions over time in order to generate 
an adequate immune response against invading pathogens without causing harm-
ful tissue destruction.
Responses that do not extinguish the infection are not desired, and shutting 
them off  as well as initiating a modulated response is thus an important feature of 
T cells. In conclusion, we suggest that in T1D this ‘editing function’ of T cells is dis-
rupted and the phenotype commitment of Tregs and eff ector T cells is disturbed. 
Th is, in turn may lead to the activation of self-antigen-specifi c eff ector T cells that 
were initially released from the thymus as natural Tregs. Th is hypothesis provides 
a topic for the future studies based on the results of this doctoral thesis as well as 
fi ndings presented by others.
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